Multiple hypervirulent methicillin-sensitive Staphylococcus aureus lineages 1

#### contribute towards poor patient outcomes in orthopedic device-related 2

- infections 3
- 4
- Virginia Post<sup>a</sup>\*, Ben Pascoe<sup>b,c,d</sup>\*, Evangelos Mourkas<sup>c</sup>, Jessica K. Calland<sup>e</sup>, Matthew 5
- D. Hitchings<sup>f</sup>, Christoph Erichsen<sup>g</sup>, Julian Fischer<sup>g</sup>, Mario Morgenstern<sup>h</sup>, R. Geoff 6
- Richards<sup>a</sup>, Samuel K. Sheppard<sup>c#</sup> & T. Fintan Moriartv<sup>a,h#</sup> 7
- 8
- <sup>a</sup>AO Research Institute Davos, Davos, Switzerland 9
- <sup>b</sup>Centre for Genomic Pathogen Surveillance, Big Data Institute, University of Oxford, 10
- 11 Oxford, United Kingdom
- <sup>c</sup>Ineos Oxford Institute of Antimicrobial Research, Department of Biology, University 12
- 13 of Oxford, Oxford, United Kingdom
- <sup>d</sup>Faculty of Veterinary Medicine, Chiang Mai University, Chiang Mai, Thailand 14
- <sup>e</sup>Oslo Centre for Biostatistics and Epidemiology, Oslo University Hospital, Oslo, 15 Norway 16
- <sup>†</sup>Swansea University Medical School, Swansea University, Swansea, United Kingdom 17
- <sup>9</sup>Department of Trauma Surgery, Trauma Centre Murnau, Murnau, Germany 18
- <sup>h</sup>Department of Orthopedic and Trauma Surgery, University Hospital Basel, 19
- 20 Switzerland
- 21
- **Running title:** Orthopedic device related *S. aureus* infections 22

- \*Address correspondence to: T. Fintan Moriarty, fintan, moriarty@aofoundation.org 24 or Samuel K. Sheppard, samuel.sheppard@biology.ox.ac.uk
- 25
- \*VP and BP contributed equally to this work. SKS and TFM contributed equally to this 26 work. 27
- 28
- 29

#### 30 Abstract

31 Staphylococci are the most common cause of orthopedic device-related infections (ODRIs), with Staphylococcus aureus responsible for a third or more of cases. This 32 33 prospective clinical and laboratory study investigated the association of genomic and 34 phenotypic variation with treatment outcomes in ODRI isolates. Eighty-six invasive S. 35 aureus isolates were collected from patients with ODRI, and clinical outcome was 36 assessed after a follow-up examination of 24 months. Each patient was then 37 considered to have been "cured" or "not cured" based on predefined clinical criteria. 38 Whole genome sequencing and molecular characterization identified isolates belonging to globally circulating community- and hospital-acquired pandemic 39 40 lineages. Most isolates were phenotypically susceptible to methicillin and lacked the 41 SCC*mec* cassette (MSSA), but contained several (hyper) virulence genes, including 42 toxins and biofilm genes. While recognizing the role of the host immune response, we identify characteristics of isolate genomes that, with larger datasets, could help 43 44 contribute to infection severity or clinical outcome predictions. While this and several 45 other studies reinforce the role antibiotic resistance (e.g., MRSA infection) has on 46 treatment failure, it is important not to overlook MSSA that can cause equally 47 destructive infections and lead to poor patient outcomes.

48

49 **Keywords** *Staphylococcus aureus;* MRSA; MSSA; virulence factors; antibiotic

<sup>50</sup> resistance; orthopedic device-related infections.

#### 52 **Importance**

Staphylococcus aureus is a prominent cause of orthopedic device-associated 53 infections, yet little is known about how the infecting pathogen, and specifically the 54 55 repertoire of genome-encoded virulence factors can impact treatment outcome. Past 56 studies have focused on distinguishing commensal from invasive S. aureus isolates 57 but in this study, we aim to investigate traits in infecting isolates that influence patient 58 outcomes. Invasive S. aureus isolates were collected from orthopedic-device related 59 infection patients and categorized according to the success of subsequent treatment 60 ("cured" /"not cured"), as determined following hospital discharge two years after initial presentation. Several MSSA hypervirulent clones were associated with a "not 61 62 cured" clinical outcome. Improved understanding of the bacterial traits associated 63 with treatment failure in ODRI will inform the risk assessment, prognosis, and therapy 64 of these infections.

#### 66 Introduction

67 The most challenging complication in orthopedic surgery is orthopedic-device related infection (ODRI), with incidence ranging from 0.7 % to 4.2 % for elective orthopedic 68 69 surgeries (1-4). Incidence increases to over 30 % following operative fixation of 70 complex open fractures (5, 6). While patient health is a key risk factor (including a 71 high BMI and chronic immunosuppression) for poor treatment outcomes (7, 8), there 72 is evidence that pathogen genetic diversity can be an indicator of patient outcome 73 (9–12). Staphylococcus aureus is the most common infecting agent (2, 3, 13–15) and 74 treatment outcome is often complicated by infection with antimicrobial resistant 75 lineages e.g., methicillin-resistant S. aureus (MRSA) (8, 16). Combined with high 76 virulence potential, MRSA are difficult to treat and are a global healthcare concern. 77 Despite this. predicting treatment outcomes based on bacterial 78 phenotypes/genotypes remains difficult (8, 10, 11, 17).

79

80 Hypervirulent pandemic clonal lineages have helped spread S. aureus around the 81 world and the geographic distribution of many lineages is dynamic, with different lineages dominating infections in specific global regions (18, 19). Waves of MRSA 82 83 lineages have risen and been replaced since the emergence of MRSA in the 1940s 84 (18, 20). These highly structured populations can be grouped into clonal complexes 85 (CCs) that share five or more alleles at seven multi-locus sequence typing (MLST) loci (21-23). Community-associated MRSA (CA-MRSA) have begun to replace 86 hospital-associated MRSA (HA-MRSA) as the dominant epidemic strains (24). The 87 88 most prevalent lineages include 5 global community acquired (CA-MRSA) genotypes 89 CC1, CC8, CC30, CC59 and CC80. The most common hospital-acquired lineages 90 are CC5, CC22 (UK), CC239 and CC45 (21–23). Combining MLST with traditional 91 molecular typing techniques such as identification of the staphylococcal cassette 92 chromosome mec (SCCmec) (25) and spa repeat regions (26) can provide a 93 nomenclature to describe relevant epidemic clones can be provided. Lineages can 94 acquire advantageous traits, such as antibiotic resistance, which proliferate in the 95 population through the decedents of successful strains. This likely occurs in many 96 instances, however, the extent of this in the context of ODRI remains to be 97 determined.

98

Despite the growing concern of MRSA lineages, MSSA isolates are often the most 99 100 common in invasive surgery-related infections (27, 28). Convergent evolution in several CA- lineages potentially balances the fitness costs of expressing AMR genes 101 102 with the acquisition of multiple virulence factors (29-32). Specific genes encoding 103 putative virulence factors in invasive S. aureus disease involve evasion of immune 104 defenses, including the ability to adhere to and invade host tissues - essential for 105 ODRI (33, 34). A large body of work has identified many virulence factors, including 106 Microbial Surface Components Recognizing Adhesive Matrix Molecules 107 (MSCRAMMs), the polysaccharide intercellular adhesion (PIA), the Staphylococcal protein A, extracellular proteins such as coagulase, Staphylococcal enterotoxins 108 109 (SE), exfoliatins (ET), toxic shock syndrome toxin (TSST), staphyloxanthin, 110 hemolysins and Panton Valentine leukocidin (PVL) that have a crucial impact on the 111 pathogenicity of S. aureus infections (35–38). Genome-wide association studies have been applied to numerous bacterial species (39, 40), and identified genes or genetic 112 113 elements associated with disease that transcend clonal patterns of inheritance (not 114 confined to specific lineages) in Staphylococci. Phenotype filtering techniques have 115 attempted to assess patient risk and predict disease outcome from genetic data 116 based on enrichment for disease-associated traits (12, 41–43). GWAS approaches have shown promising disease prediction results (31, 43, 44), as well as AMR 117 profiles (45). As in other bacterial species (46–48), a better understanding of genome 118 and transcriptome variation in hypervirulent infection types shows promise for our 119 120 ability to predict disease severity in Staphylococci (49).

121

In this study we investigate the association between treatment outcomes determined 2 years post-operatively in patients with *S. aureus* ODRI and phenotypic and genotypic features of the infecting pathogen. Building on recent studies aiming to predict *S. aureus* virulence from genome sequence (43, 44), we aim to distinguish high risk lineages, isolates and genes. These features were correlated with mortality rate in a simplified virulence model using *Galleria mellonella*.

128

#### 129 **Results**

S. aureus isolates were collected from 86 patients undergoing operative revision of 130 an ODRI (Supplementary table S1). Patient outcomes were assessed after a 2-year 131 132 follow-up period and "cured" patients were free of infection, surgical and systemic 133 antibiotic therapy had ceased with function of the affected joint or limb restored. If 134 one or more of these parameters was negative, patients were considered to have 135 had a "not cured" outcome (8, 12). Most patients enrolled in the study received 136 successful treatment and were among the "cured" cohort (Table 1; n= 65/86; 75.6%). 137 Treatment was unsuccessful in 21 patients (n=21/86; 24.4% "not-cured") and multiple revision surgeries were necessary for nearly all patients (n=83/86; 96.5%). 138

139

#### 140 Host-associated risk factors

Extensive patient data, types of implanted devices and clinical presentation were recorded for each infected patient (**Table 1**). Additionally, the effects of patient comorbidities (such as diabetes or obesity), fracture types or the time of symptoms onset on treatment outcome were analyzed (**Table 2**). None of these prognostic factors alone significantly decreased cure rate.

146

#### 147 Multiple lineages contribute to poor patient outcome

A maximum-likelihood phylogeny was constructed based on shared coding 148 sequences, present in 95% or more isolates (Figure 1A; Supplementary table S1). 149 The collected isolates were genetically diverse and represented 19 different 150 sequence types (STs) (Figure 1B) based on the 7 loci scheme for S. aureus and 151 152 could be grouped into 18 clonal complexes (CCs) based on 5 or more shared MLST loci (21). No clear clustering was observed between "cured" and "not-cured" isolates. 153 Consistent with other European surveillance efforts, six of our seven most common 154 lineages matched common pandemic S. aureus lineages (CC5, CC8, CC22, CC30, 155 CC45 and CC59) previously identified by the ESCMID study group (collected from 26 156 157 European countries between 2006-7) (50). Our isolates predominantly lacked the SCCmec cassette, which confers methicillin resistance and were classified as 158 159 methicillin-susceptible S. aureus (MSSA; n= 81/86; 94%) (Figure 1C).

160

161 Most of our isolates (n=48/86; 55.8%) were from community-acquired lineages 162 (MSSA or SCC*mec* types I, II, III), including CC30 which was the most common

clonal complex identified in our collection (n=14/86; 16.3%) (Figure 1A+B). In more
than three quarters (n=11/14; 78.6%,) of cases where this clonal complex was
identified, the patient was deemed to have had a good outcome and a "cured" status
(Supplementary table S2). A minority of isolates were identified from other CAlineages, CC8 (n=6) and CC59 (n=5), CC45 (n=9), CC7 (n=8), CC15 (n=6). No
isolates were sampled from two common pandemic CA- lineages, CC1 and CC80.

169

170 Many isolates we identified were from well described hospital-acquired lineages 171 (n=23/86; 26.7%), including the globally distributed CC5 lineage (n=12) (Figure **1A+B**). Infections from this CC were often unresolved (n=6/12; 50%) and posed the 172 173 highest risk of a "not cured" patient outcome. CC22 is the most common sequence type identified from clinical infections, particularly in the UK (51, 52), but was the 3<sup>rd</sup> 174 175 most sampled CC in our collection (n=11/86; 12.8%). This clonal complex was implicated in a "not cured" patient outcome on only one occasion. All other CCs were 176 represented by fewer than 5 isolates. One isolate was isolated from the livestock 177 178 associated lineage, CC398 (n=1).

179

#### 180 Accessory genome differences in ODRI isolates

181 ODRI that leads to a "not cured" patient outcome is a complex process, which is affected by genetic and environmental differences in the host (Table 2) as well as 182 variation in the infecting bacterial population. To investigate differences in gene 183 presence between isolates showing phenotypic variation, we further investigated 184 185 genes in the accessory genome. We characterized the pangenome using PIRATE 186 (53) with 86 isolates plus 8 reference strains (to help preserve gene nomenclature). In total, PIRATE identified 4,142 gene clusters, of which over half were characterized 187 as core genes (present in 95% or more of the isolates; 2,150 genes; 52%). This was 188 consistent with core genome estimates from other S. aureus collections (54-57). The 189 190 accessory genome consisted of 1,992 genes (present in fewer than 95% of isolates), 191 representing ~48% of the pangenome. A large proportion of the accessory genome 192 (78%) was present in fewer than 25% of isolates (1,57/1,992 accessory genes; 193 **Supplementary table S3**). Core and accessory genome differences were visualized 194 in phandango (58) (Figure S1A). Consistent with the clonal nature of S. aureus, isolates grouped by accessory genome content (using poppunk) clustered similarly to 195 196 the clonal frame (Figure S1BC) (59).

#### 197

#### 198 Distribution of known virulence and AMR genes

199 All S. aureus isolates were sampled from invasive disease cases and contained 200 many known virulence genes, with between 50 and 69 genes identified in each 201 isolate from the VfDB database (average: 63; update March 2021). Nearly half of 202 these putative virulence factors were present in all isolates (35 of 79; 44%), including 203 the genes: adsA (phagocytosis escape), aur (metalloproteinase), geh (lipase), hla ( $\alpha$ -204 hemolysin), hlqAB (y-hemolysin), hysA (hyaluronate lysate), icaABDR (biofilm 205 formation), isdAB (surface proteins), lip (lipase), srtB (surface protein anchor), 206 sspABC (adhesion) and much of the *cap8* capsule operon (Figure 2A). Distribution 207 of virulence genes between the two clinical outcome groups ("cured" and "not cured") 208 was also considered. The methicillin resistance gene, mecA was more prevalent in 209 the "not cured" outcome group (n=2/21; 9.5%) compared to the "cured" group (n=3/65; 4.6%). Also, the presence of the bbp gene (bone sialprotein binding) 210 211 (n=20/21; 95.2% versus n=58/65; 89.2%) and *ebpS* gene (elastin binding) (n=21/21; 212 100.0% versus n=60/65; 92.3%) were found to be more prevalent in the "not cured" outcome group than in the "cured" outcome group, but this was not statistically 213 214 significant. (Supplementary table S4).

215

As most isolates were MSSA, there were very few antimicrobial resistance genes 216 (ARGs) identified through nucleotide comparisons with the AMR finder Plus database 217 (Supplementary table S5). Differences were observed between clonal complexes 218 219 for the numbers of virulence and AMR determinants (Figure 2B). In common with 220 other studies, we identified slightly fewer virulence genes, but more ARGs in hospital-221 associated lineages. On average there were 60.3 virulence genes and 4.4 ARGs in 222 HA lineages, compared with 63.8 virulence and 4.1 ARGs in community associated 223 lineages. Six MSSA clones were represented by three or more isolates, of which five 224 represented more than a third of our isolates (8 of 21; 38%) from patients who 225 experienced a "not cured" outcome (Figure 2C). Two clones posed a particularly 226 high risk to patients with 40% (2 of 5) of CC5-t002-MSSA and CC59-t216-MSSA 227 isolates developing a "not cured" patient outcome. A quarter of patients (2 of 8) infected by CC7-t091-MSSA also experienced a "not cured" outcome, while those 228 229 infected by the CC22-t005-MSSA clone all recovered.

230

# Both "cured" and "not cured" isolates induced high mortality in a Galleria mellonella model

A selection of isolates (10 "not cured" and 10 "cured") were used to challenge G. 233 mellonella larvae. Bacterial suspensions were injected into larvae (average inoculum 234 of  $2.75 \times 10^6$  CFU/larvae; range:  $1.87 \times 10^6$  to  $4.29 \times 10^6$ ) and incubated up to 120 hours. 235 However, high mortality was observed in a proportion of isolates in both outcome 236 237 groups (Figure 3AB). This may not be surprising as all isolates were from infection 238 cases, and all were found to possess at least 12 toxin genes. Further analysis of the 239 Galleria virulence results identified differences between the average mortality scores 240 when specific putative virulence genes were present (Figure 3C). Differences in 241 gene content between isolates were quantified and scored using SCOARY (60). We 242 report minus log<sub>10</sub> of the naïve p-value for the null hypothesis that the 243 presence/absence of this gene is unrelated to the trait status (-log<sub>10</sub>>2 equivalent to naive p-value <0.01). We identified four gene clusters associated with increased 244 245 killing during the Galleria infection model (Figure 3D). Three of which (g01257, 246 g01221 and g01491) demonstrated more than 90% sequence similarity with a SOS 247 response-activated pathogenicity island shared between S. aureus and S. 248 epidermidis isolates (SACOL0900-0904) (54, 61). The fourth gene cluster (g03516) 249 identified was identical (100% nucleotide similarity over 100% of the gene) to the msaC gene (SACOL1438/SAUSA300\_1296). As an uncoded member of the 250 msaABCR operon, this locus has an indirect role in virulence factors aur, scp, ssp 251 and spl and contributes to increased virulence, biofilm formation and triggers the 252 253 onset of bacterial persistence (62-64)(Supplementary file S4).

254

# Isolate phenotypic variation may contribute to the onset of infection, but does *little to influence patient outcome*

We tested laboratory phenotypes associated with increased virulence and compared 257 258 these with patient outcome. Individually, none of the phenotypes contributed 259 significantly to a "not cured" patient outcome (Table 3). Isolates were subject to 260 antimicrobial susceptibility profiling (29 antibiotics), biofilm formation, hemolysis 261 activity and staphyloxanthin production (Supplementary table S6). No isolate was considered extensively or pan drug resistant, although 4 were considered multi-drug 262 263 resistant (resistant to three or more different classes of antibiotic). More than half 264 (n=51/86; 59.3 %) of all collected isolates were unable to form a thick biofilm under

laboratory conditions. Furthermore, 61.6 % (n=53/86) of all isolates produced staphyloxanthin and 39.5 % (n=34/86) showed hemolytic activity (**Table 3**). Isolates that demonstrated hemolytic activity contribute to a "cured" patient outcome (≥90% confidence; p=0.090, **Table 3**). Isolates that were able to produce a thick biofilm were often also able to produce staphyloxanthin (n=27/35; 77.1%; **Table 4**). However, poor biofilm forming isolates that produced staphyloxanthin (n=26/51; 51.0%) were detrimentally associated with a "not cured" patient outcome (n=15/26; 57.7%).

272

#### 273 Genes associated with different virulence phenotypes

Differences in gene content between phenotypes were quantified and scored using 274 275 SCOARY, reporting the minus log<sub>10</sub> of the naive p-value for the null hypothesis that 276 the presence/absence of this gene is unrelated to the trait status (-log<sub>10</sub>>2 equivalent 277 to naive p-value <0.01; Supplementary table S7). We identify genes associated with six different phenotypes, including patient outcome, biofilm formation, hemolysis, 278 multi-drug resistance, methicillin resistance and staphyloxanthin production (Figure 279 280 4). An uncharacterized membrane protein (g02811) and a gene from the SA97 virulent bacteriophage (q03902) were associated with a "not cured" patient outcome 281 282  $(-\log_{10}>2)$ ; naïve p-value <0.01; Figure 4A). Genes commonly found as part of the 283 SCCmec cassette (mecA, paaZ, upgQ and mecRI) were associated with methicillin resistance, and were among the gene clusters that demonstrated the strongest 284 association with any phenotype ( $-\log_{10}>6$ ; naïve p-value  $<2*10^{-7}$ ; Figure 4B). Several 285 hypothetical gene clusters were associated with biofilm formation (8 genes with naïve 286 287 p-value <0.01; -log<sub>10</sub>>2; **Figure 4C**).

288

289 The presence of several genes (27 genes with  $-\log_{10}>2$ , lowest p-value: 0.00017), 290 including enterotoxins A and D and the collagen adhesin *cna* were associated with 291 hemolysis production (Figure 4D). Despite only four isolates that were classed as MDR, the presence of 93 genes (lowest p-value: 4.68x10<sup>-6</sup>) were associated with 292 293 phenotypically measured MDR, which included several members of the SCCmec 294 cassette, the erythromycin resistance-associated ermA and the aminoglycoside 295 resistance determinant, ant1 Figure 4E). Several enterotoxin genes were also 296 associated with MDR, along with the biofilm-associated gene xerC. The chemotaxis 297 inhibiting gene, *chp* was the only gene associated with staphyloxanthin production in 298 our dataset (Figure 4F).

299

## 300 Genes linked to phenotypes that influence patient outcomes are more 301 recombinogenic

302 Finally, we investigated the role of recombination in isolates that led to a poorer 303 patient outcome. On average, isolates that led to a "not cured" patient outcome 304 demonstrated the highest rates of recombination (Figure S2). However, genomes of 305 isolates from patients who were successfully 'cured' were predicted to have included 306 more recombination events. This is likely influenced by a small number of highly 307 recombinogenic genomes that were predicted to have undergone extensive 308 recombination (Supplementary table S8). Genes that were associated with any of 309 our tested phenotypes demonstrated greater clonal inheritance than genes in the core genome. Meaning that phylogenies constructed from sequences of the 310 311 individual genes were consistent with the phylogeny constructed from the core genome (Figure 4G). The mean consistency index (CI) was significantly higher 312 313 (Mann Whitney test; U = 78998, p < 0.0001) among virulence phenotype-associated 314 genes (0.7766  $\pm$  0.2418) compared with the average for all core genes (0.6943  $\pm$ 315 0.1408). Taken together, the highly clonal population structure of S. aureus (long 316 branches) - particularly those genes involved in virulence - and higher rates of 317 recombination between lineages permits co-evolution of several successful hypervirulent lineages that can contribute to "not cured" patient outcomes in ODRI. 318

#### 319 Discussion

320 Despite advances in many aspects of emergency and orthopedic trauma care, ODRI 321 persists as a challenge for the treating physicians and a significant burden for the 322 patient. The interaction between the host immune system and invading isolates is 323 complex and is not only affected by variation in host and bacterial genetics, but also 324 by factors such as host wellbeing and general health (e.g. obesity). In a similar way 325 to how the host deploys several different types of host defense mechanisms, bacteria 326 are armed with a toolbox of different virulence factors. We used a combination of 327 phenotype testing, an *in vivo* infection model and *in silico* genome characterization to 328 identify lineages and virulence factors that may contribute to the risk of poor patient 329 outcomes following ODRI.

330

331 Isolates from patients who experienced a "not cured" outcome did not cluster by core 332 or accessory genomes (Figure 1A). The most common clonal complex associated 333 with a poor patient outcome in our collection was CC5 (50%; Figure 1B). CC5 is 334 highly recombinogenic and able to infect multiple host species (65, 66) and is often 335 isolated from human infections, particularly skin and bone infections (55, 67). While 336 infection is often caused by MRSA, there is growing concern for the spread of hypervirulent MSSA clones (67, 68). Nearly all the isolates we collected were 337 sensitive to methicillin and lacked a functional SCCmec cassette (9 of 12 CC5 338 339 isolates). The gain and loss of SCCmec cassettes by multiple S. aureus clones 340 continues to blur the differentiation of community-associated (CA) and hospital-341 associated (HA) S. aureus lineages (69, 70).

342

343 Since the emergence and epidemic spread of USA300 (CC8) clone in the early 344 2000s (30, 71, 72), CA- lineages have dominated infection surveillance studies (19, 345 71, 72). CA- lineages are typically thought to carry larger - more cumbersome, and less resistant - SCCmec types I, II and III, and often carry toxin genes such as the 346 347 PVL genes. While traditional HA-S. aureus lineages carry smaller SCCmec cassettes 348 that are more difficult to disrupt, which are maintained by successive generations. 349 Several HA-lineages rose to prominence around the world, only to have been 350 replaced as the most common lineages in human infections in specific regions; 351 including the rise of CC22 in the UK and Europe (18, 73–75), and replacement of HA-352 MRSA-ST239 by CA-MRSA-ST59 in China (19). It is has been suggested that

increased virulence, coupled with fewer putative AMR genes has contributed to the
success of these CA-clones/lineages (31, 76). This was the case in our collection
with more virulence genes and fewer ARGs found in CA-lineages compared to HAlineages (Figure 2B & Table S5).

357

358 Isolates from the most common European lineage (CC22) were common among our 359 collection of invasive isolates and were the most likely to lead to a "cured" patient 360 outcome (Figure 1B). Further characterization of the specific clones in our collection 361 identified 6 common clones, including a CC22-t005-MSSA clone that did not lead to a 362 "not cured" patient outcome in any of the 5 patients it infected (Figure 2C). The five 363 remaining clones that were identified in three of more patients were responsible for 364 more than a third of the "not cured" patient outcomes. The CC59-t216-MSSA and 365 CC5-t002-MSSA clones posed the highest risk, with 40% of patients infected by these clones developing a poor outcome. The CC5-t002-MRSA clone has been 366 367 frequently observed, including studies from China and Iran where it exhibited 368 extensive mupirocin resistance, MDR and contained several virulence toxins (PVL 369 and tsst-1) (77, 78).

370

371 All isolates we collected were from invasive ODRI and contained at least 50 known virulence genes (Figure 2AB). Infection is complex and the function of any virulence 372 gene is context dependent and a simple sum of the number of putative virulence 373 374 elements is unlikely to be a good proxy for the infective potential of an isolate. All 375 isolates in our collection were able to colonize and cause infection, but variation in 376 additional virulence factors will influence disease progression and host evasion. Despite relatively small sample numbers, we were able to identify putative virulence-377 378 associated genes from an *in vivo* infection model and phenotypic assays, including 379 biofilm production, antimicrobial susceptibility (and MDR), hemolysis and 380 staphyloxanthin production.

381

Similar assays in *S. epidemidis* identified biofilm formation as key to establishing an ODRI through adhesion to implant surfaces (12, 43) and contributed towards a poorer clinical outcome, persistence and recurrence (8). However, this was not the case in the current study. Although 40% of the *S. aureus* isolates were able to form a strong biofilm, no clear influence on patient outcome was observed (**Table 3**). Armed

with a suite of extracellular toxins, S. aureus can often cause more severe acute 387 388 infections (79), while S. epidermidis is often associated with less severe, chronic 389 infection – where strong biofilm formation on implants and dead tissue may be more 390 relevant (80-82). In vitro Staphyloxanthin production leads to increased pathogenicity of S. aureus (83, 84), and 61% of our isolates were able to produce staphyloxanthin 391 392 (**Table S6**). This level of prevalence is consistent with the observation by Post *et al.* 393 whereby 56% of 305 isolates from implant and non-implant infections were 394 staphyloxanthin producers (85). The chemotaxis inhibitor protein (CHIPS), encoded 395 by chp was the only gene we found associated with staphyloxanthin production 396 (Figure 4G). CHIPS ability to help evade host immune responses pose the potential 397 for more severe and chronic infections (86, 87). Although it was not independently 398 associated with "not cured" in our study population.

399

In hypervirulent MSSA lineages and clones, increased carriage of virulence genes is 400 401 balanced against limited carriage of AMR genes. We observed this in our collection, 402 with relatively few isolates resistant to multiple antibiotics (Figure 2B & Table S5), 403 and lower rates of MRSA isolates compared to other studies (7% MRSA and 10% 404 MDR). Rates of MRSA (27% & 24%) were much higher in other studies of ODRI (10, 405 11). Both these previous studies involved patients with a median age above 60, and patients infected with MRSA experienced lower cure rates (57%) than for MSSA-406 infected patients (72%) or CoNS (82%) (10). Very high rates of methicillin resistance 407 408 have been observed in S. epidermidis ODRI isolates, which is consistent with 409 different modes of infection between the species (73% MRSE and 76% MDR) (8). 410 Elderly patients are more likely to suffer from infection with resistant bacteria due to repeated hospital stays and multi-morbidity (88, 89), and may partially explain the 411 reduced number of MRSA isolates in our collection. Although only present in a small 412 number of our isolates (n=6; 7%), methicillin resistance was associated with a "not 413 cured" outcome (2 of 6; 33.3%; Table 3). This is consistent with many other studies 414 415 that have highlighted the detrimental effect of methicillin resistance on treatment success (43, 55, 90). 416

417

Deep branching clades and highly structured clustering of isolates is evidence of the strong selection pressures that have driven the evolution of *S. aureus*. Distinct *S. aureus* lineages are found at markedly different prevalence globally, including

421 hypervirulent sub-lineages (74, 91). Waves of pandemic sub-lineages have been 422 described within CC30 - initially MSSA, before being replaced by MRSA variants (18, 423 19, 74). Independent acquisition of virulence determinants in these lineages was 424 associated with the rise and fall of these lineages and horizontal gene transfer (HGT) 425 likely has an important role in the accumulation of virulence factors. This lineage 426 specific accumulation of virulence genes makes traditional identification of virulence 427 factors difficult. Genome-wide association studies that can account for these lineage 428 effects (43, 44, 90, 92), or can differentiate between the types of association, are 429 potentially useful (93). Furthermore, the inclusion of the pangenome analyses 430 (including mobile elements and intergenic regions) and covarying SNPs and genes 431 (epistasis) (94, 95), combined with appropriate phenotypic validation and/or 432 transcriptome profiling will greatly enhance understanding of the contribution of 433 pathogen genetic variation on disease progression (49).

434

435 Infection is clearly a complex process influenced by the host immune system and 436 genotypic variation within the invading pathogen. Here, we only tested a single S. 437 aureus colony from each patient. However, there can be considerable diversity 438 among the commensal and infective isolates within a single person (96-99). Small 439 colony variants (SCV) (100, 101), persistence (102, 103) and dormancy (104, 105) also help protect invading cells from the host immune system and evade 440 antimicrobial treatment. While the isolates collected here have already colonized host 441 442 subcutaneous tissue and established an infection, our aim was to delineate factors 443 that contribute to poorer patient outcomes. Our results are consistent with a complex 444 balance between virulence and colonization (32), involving core and accessory genome elements, and provide some evidence that characterization of common 445 446 emerging clones and lineages may help disease outcome prediction.

#### 447 Materials and methods

448

#### 449 Clinical data and Staphylococcus aureus collection

450 The clinical data and S. aureus collection was part of a prospective study performed 451 between November 2011 and September 2013 at BGU Murnau in Germany (12) 452 which was approved by the local ethical committee Ethik-Kommission der 453 Bayerischen Landesärztekammer under approval number 12063 and registered with 454 https://clinicaltrials.gov with identifier NCT02971657. All patients enrolled in the study 455 were aged 18 or older and provided informed written consent. Patient inclusion criteria were culture-positive S. aureus infection involving fracture related infection 456 457 (FRI) or periprosthetic joint infections (PJI). All patient details were anonymized, and 458 S. aureus isolates given genome database identifiers (BIGSids), study identifiers 459 (ARI-number) and sample laboratory identifiers (Lab-ID). Associated clinical data are 460 summarized in **Table S1**. After an average of 23 months follow-up (FUP) patients 461 were assessed for treatment outcome. When patients did not complete a follow-up 462 appointment, the clinical outcome was assessed at the time of hospital discharge. "Cured" patients were free of infection, surgical and systemic antibiotic therapy had 463 464 ceased with function of the affected joint or limb restored. If one or more of these 465 parameters were negative, patients were considered to have had a "not cured" 466 outcome (8, 12).

467

#### 468 **Genome sequencing and assembly**

S. aureus colonies were cultured in 5 ml Tryptone Soy Broth at 37 °C with overnight 469 470 shaking. DNA was extracted using the QIAamp DNA Mini Kit (Qiagen, Germany) 471 according to manufacturer's instructions with the addition of 1.5 µg/µL lysostaphin (Sigma-Aldrich, Buchs, Switzerland) and 2 µg/ml lysozyme (Sigma-Aldrich, Buchs, 472 Switzerland) to facilitate cell lysis. DNA was quantified using a spectrophotometer 473 prior to sending for sequencing by Microsynth AG (Switzerland) using an Illumina 474 475 MiSeq benchtop sequencer. Sequencing libraries were prepared using Nextera XT library preparation kits (v2) and paired end 250 bp reads generated with the MiSeq 476 477 run kit (v2). Short read paired-end data was assembled de novo with SPAdes (version 3.3.0; using the -careful command)(106) and assessed for quality (n=86 478 479 genomes contained < 500 contigs). Average assembled genomes were 2,771,938 bp

in length (range: 2,638,312 - 2,962,075 bp) consisting of 113 contigs (range: 29 –
358 contigs) with an N50 of 43,492 bp (range: 5,729 – 109,980) (Table S2).

482

## 483 Genome archiving, multiple genome alignments and construction of isolate 484 genealogies

485 An alignment of all 86 S. aureus isolates was constructed from concatenated gene 486 sequences of all core genes (found in ≥95% isolates) using MAFFT (version 7)(107) 487 on a gene-by-gene basis (size: 2,138,455 bp; Supplementary file 1). A maximum-488 likelihood phylogenies were constructed using a GTR + I + G substitution model and ultra-fast bootstrapping (1,000 bootstraps) implemented in IQ-TREE (version 489 490 2.0.3)(108, 109) and visualized on Microreact: https://microreact.org/project/Post-Pascoe-Saureus/0f0c26fb (Supplementary file S3) (110). Collection also shared on 491 492 the pathogen watch website (https://pathogen.watch/collection/7rgjyrzz3xoc-postand-pascoe-et-al-2022-hypervirulent-mssa-from-odri). 493

494

#### 495 Molecular typing and genome characterization

Our publicly available BIGSdb database (<u>https://sheppardlab.com/resources/</u>)
includes functionality to determine multi-locus sequence type (MLST) profiles defined
by the Staphylococcal pubMLST database (<u>https://pubmlst.org/saureus</u>; accessed
March 2019) (111). Staphopia (version 1.0.0) was used to define *SCCmec* types
(112) and *spa* types were typed *in silico* using spaTyper v1.0 (**Supplementary table S2**) (113).

502

#### 503 Care and accessory genome characterization

All unique genes present in at least one of our isolates (or eight reference strains) 504 were identified by automated annotation using PROKKA (version 1.13) followed by 505 PIRATE, a pangenomics tool that allows for orthologue gene clustering in bacteria 506 (Supplementary table S3; Supplementary file S3). Genes families in PIRATE were 507 508 defined using a wide range of amino acid percentage sequence identity thresholds for Markov Cluster algorithm (MCL) clustering (45, 50, 60, 70, 80, 90, 95, 98). Core 509 510 genes were defined as present in 95% of the genomes and accessory genes as present in at least one isolate (Supplementary figure S1A). The pangenome was 511 512 visualized using phandango, as a matrix of gene presence alongside a core genome 513 phylogeny (58). Pairwise core and accessory genome distances were compared

using PopPunk (version 1.1.4), which uses pairwise nucleotide k-mer comparisons to
distinguish shared sequence and gene content to identify divergence of the
accessory genome in relation to the core genome. A two-component Gaussian
mixture model was used to construct a network to define clusters and visualized with
microreact (Supplementary figure S1BC) (59, 110).

519

#### 520 Identification of known virulence traits and antimicrobial resistance genes

521 The presence of putative virulence factors and antimicrobial resistance genes were 522 identified from assembled genomes using ABRICATE (v0.3) (59). Putative virulence genes were detected through comparison with reference nucleotide sequences in the 523 VfDb (default settings: ≥70% identity over ≥50% of the gene; **Supplementary table** 524 **S4**) (114). Antimicrobial resistance genes were identified using the NCBI AMR finder 525 Plus (115) and CARD (116) databases (19<sup>th</sup> April, 2020 update). Results for both 526 AMR databases were similar, with the CARD database identifying additional AMR 527 528 associated genes. We report the results from the curated AMR finder Plus database 529 (Supplementary table S5).

530

#### 531 Phenotype testing

532 Antibiotic susceptibility testing: Minimum inhibitory concentrations (MICs) for 29 antibiotics were determined using a Vitek2 machine (bioMérieux Vitek Inc., USA) as 533 described previously (8, 12). Susceptibility breakpoints were defined according to the 534 definitions of the European Committee of Antimicrobial Susceptibility Testing 535 (EUCAST) and isolates resistant to 3 or more antimicrobial classes were defined as 536 537 multidrug resistant (MDR)(118). The Vitek2 results for oxacillin and cefoxitin were a proxy for methicillin-resistance. Staphyloxanthin production: 538 used as Staphyloxanthin production indicated by a yellow-orange pigmentation of S. aureus 539 colonies as well as *Haemolysin activity:* Haemolysis activity of *S. aureus* strains 540 was evaluated as previously described (119). Biofilm formation: was also assayed 541 542 as described previously (8, 12, 85, 120). Association amongst and between the clinical parameters, bacterial phenotypes, clades and presence/absence of genes 543 544 were analyzed statistically using Chi-square test. Statistical analyses were performed using SPSS (Version 23, IBM, USA) or GraphPad prism 6 (GraphPad Software, Inc.; 545 Supplementary table S6). 546

In vivo virulence and survival assay in Galleria mellonella larvae: The 548 549 invertebrate G. mellonella infection model was used to study the virulence of the S. aureus strains as previously described (121, 122). G. mellonella were obtained at 550 pre-larval stage (Entomos AG, Zurich Switzerland). Larvae were grown at 30 °C in 551 the dark and groups of ten larvae in the final instar larval stage weighing 200-552 400 mg were used in all assays. A bacterial suspension of 10<sup>6</sup> CFU/ml was 553 prepared. Quantitative culture of a sample from each bacterial suspension was 554 performed immediately after preparation by ten-fold serial dilution and plating on 555 556 Tryptone Soy Agar plates to check the actual total viable count of the prepared suspension. Bacterial inoculates (10 µl) were injected into the last left pro-leg into the 557 558 hemocoel of the last-instar larvae (200-400 mg). After injection, larvae were 559 incubated at 37 °C in the dark. Larvae were assessed daily for survival up to 5 days 560 post-injection and were evaluated according to survival, being scored as dead when they displayed no movement in response to touch. Controls included a group of 561 562 larvae that did not receive any injection and a group of larvae inoculated with sterile 563 phosphate-buffered saline (PBS). Experiments consisted of 10 larvae per bacterial 564 strain, which was repeated in three separate experiments. For G. mellonella survival 565 analysis, larvae mean survival curves were plotted using the Kaplan-Meier method 566 (GraphPad Prism 6, USA; **Supplementary table S6**).

567

#### 568 Pan-genome-wide association studies of phenotype variation

Pangenome-wide differences in gene presence were quantified using the genome-569 570 wide association software, SCOARY (version 1.6.14)(60). With only limited numbers 571 of samples in our collection, we report phylogenetically naïve differences in gene clinical laboratory 572 presence between and symptoms and phenotypes (Supplementary table S7). 573

574

#### 575 Recombination and allelic consistency

The number of polymorphisms introduced by mutation and recombination in the core genome were inferred using Gubbins (version 2.4.1)(123) for each isolate (per branch; **Supplementary table S8**).The consistency of the phylogenetic tree to patterns of variation in sequence alignments for each gene of interest was calculated as before (124, 125). Consistency indices for each single-gene alignment of 130 virulence-associated genes to a phylogeny constructed using an alignment of 2,150

core genes shared by 94 isolates, were calculated using the CI function of the RPhangorn package (126).

584

#### 585 Data availability

586 Illumina short read sequence data are archived on the Sequence Read Archive associated with BioProject accession PRJNA529795. All assembled genomes are 587 588 shared on figshare (doi: 10.6084/m9.figshare.7926866) and are available on our 589 public Staphylococcal Bacterial Isolate Genome Sequence Database (BIGSdb): 590 https://sheppardlab.com/resources/. Isolate genealogy with associated meta-data is 591 visualized (110): https://microreact.org/project/Post-Pascoeon microreact 592 Saureus/0f0c26fb. All high-performance computing was performed on MRC CLIMB 593 (127) in a bioconda environment (128).

#### 595 Acknowledgements

This work was funded by AO Trauma as part of the Clinical Priority Program, Bone 596 Infection. All high-performance computing was performed on MRC CLIMB, funded by 597 598 the Medical Research Council (MR/L015080/1 & MR/T030062/1). This publication made use of the PubMLST website (http://pubmlst.org/) developed by Keith Jolley 599 600 and Martin Maiden (129) and sited at the University of Oxford. The development of 601 that website was funded by the Wellcome Trust. The funders had no role in study 602 design, data collection and interpretation, or the decision to submit the work for 603 publication.

- 604
- All authors report no conflicts of interest relevant to this article.
- 606

#### 607 **Contributions**

- 608 Conceptualization: VP, BP, SKS, and TFM; Isolate collection: VP, CE, JF, MM, and
- TFM; Data collection and curation: VP, BP, MDH and SKS; Formal Analysis: VP, BP,
- 610 EM, JKC; Visualization: VP, BP, EM, JKC; Writing original draft: VP, BP, SKS and
- TFM; Writing Review & Editing: VP, BP, SKS and TFM; Funding Acquisition: VP,
- 612 RGR and TFM.
- 613

#### 614 Figures and Table legends

- 615 **Table 1:** Collection overview.
- 616 **Table 2:** Patient risk factors.
- 617 **Table 3:** Infection isolate prognostic phenotypes.
- **Table 4:** Phenotype associations in combination with enhanced biofilm formation.
- 619

#### 620 **Figure 1:**

621 Population structure of S. aureus isolates collected in this study. A: A 622 maximum-likelihood phylogeny was constructed with IQ-TREE, using a GTR model 623 and ultrafast bootstrapping (1000 bootstraps; version 2.0.3)(108, 109) from an 624 alignment of all isolates (n=86). Scale bar represents a genetic distance of 0.001. 625 Leaves from isolates that were "cured" are white (n=65) and those that did not 626 achieve a "cured" status are black (n=21). The tree is annotated with MLST, clonal 627 complex, methicillin resistance status, SCCmec and spa types and the presence of 628 PVL genes (indicated by colored blocks). Isolates from hospital associated lineages

are highlighted in blue. Interactive visualization is available on Microreact (110): <u>https://microreact.org/project/Post-Pascoe-Saureus/0f0c26fb</u>. The number of isolates from each (**B**) MLST clonal complexes (CC) and (**C**) methicillin resistant (MRSA) and methicillin susceptible (MSSA) lineages. The proportion of isolates that lead to a "not cured" status is shown in black.

634

#### 635 **Figure 2:**

636 Hypervirulent lineages and clones. A: Maximum-likelihood phylogeny of our 86 S. 637 aureus isolates above matrix of defined virulence factors identified using the VfDb (114). Summary boxplots of the number of virulence and antimicrobial resistance 638 639 genes (ARGs) identified in each (B) clonal complex and (C) MSSA clone 640 (represented by 3 or more isolates). All data points shown, bars show min and max. 641 Hospital-associated lineages and clones highlighted in blue. The number of isolates 642 from each MSSA clone is also shown, with the proportion of isolates from patients 643 who did not achieve a" cured" status in black.

644

#### 645 Figure 3:

646 Galleria mellonella virulence model. Kaplan-Meier survival curve of larvae infected 647 with S. aureus isolates from A: "not cured" outcome patients and from B: " cured" outcome patients. Each line represents a different S. aureus isolate injected into 10 648 larvae per isolate. Mean survival rate was calculated per isolate. Dotted line 649 represents survival of larvae injected with PBS; green line represents high survival 650 651 rate and red line indicates a high mortality rate. C: Mean kill curve scores from 652 isolates that contained each virulence factor identified by VfDb. D: Pangenome-wide 653 association study comparing isolates with high kill score (above 50% at 120 hrs) vs 654 those with low kills scores using SCOARY (60). No lineage correction was used and the phylogenetically naïve minus LOG p-value reported. Three genes from previously 655 656 identified pathogenicity island and msaC gene from the msaABCR operon were 657 associated with increased killing.

658

#### 659 Figure 4:

660 **Pangenome-wide association studies.** SCOARY was used to quantify gene 661 presence between isolates tested for six targeted virulence phenotypes (60). No 662 lineage correction was used, and the phylogenetically naïve minus LOG p-value

663 reported. Isolates were scored for phenotypic differences in (A) patient outcome; (B) 664 methicillin resistance; (C) biofilm formation; (D) hemolysis; (E) multidrug resistance; 665 and (F) staphyloxanthin production. Genes that were highly associated with a given 666 phenotype are labelled. Multiple toxin (blue circles) and SCCmec cassette (red 667 circles) genes were associated with more than one phenotype. (G) Individual gene 668 phylogenies were compared to a core phylogeny for each virulence phenotype-669 associated gene and consistency indices calculated. The two distributions were 670 significantly different (Mann Whitney test; U = 78998, p < 0.0001) between virulence 671 phenotype-associated genes ( $0.7766 \pm 0.2418$ ) compared with the average for all 672 core genes  $(0.6943 \pm 0.1408)$ .

673

#### 674 Supplementary material (figshare: <u>https://doi.org/10.6084/m9.figshare.7926866</u>)

- **Table S1:** Demographic data collected for each isolate.
- **Table S2:** Genome quality control and extended typing results.
- **Table S3:** Summary of core and accessory genome characterization with PIRATE.
- Table S4: Summary of genes identified by screening known virulence genes with theVfDB.
- **Table S5:** Summary of genes identified by screening antibiotic resistance genes with
- the AMRfinder (NCBI) and CARD databases.
- **Table S6:** Summary of virulence phenotype data.
- **Table S7:** Summary of genes associated with virulence phenotypes (SCOARY).
- **Table S8:** Per isolate recombination statistics using Gubbins.
- 685
- **Figure S1:** Accessory genome characterization.
- 687 **Figure S2**: Recombination analysis.
- 688
- 689 **Supplementary file 1:** Contigs
- 690 **Supplementary file 2:** Alignment.
- 691 **Supplementary file 3:** Phylogeny (.nwk) of 86 collected isolates.
- 692 **Supplementary file 4**: PIRATE pangenome gene families.

#### 694 References

694	Nele	
695	1.	Tschudin-Sutter S, Frei R, Dangel M, Jakob M, Balmelli C, Schaefer DJ,
696		Weisser M, Elzi L, Battegay M, Widmer AF. 2016. Validation of a treatment
697		algorithm for orthopaedic implant-related infections with device-retention-
698		results from a prospective observational cohort study. Clin Microbiol Infect
699		22:457.e1-457.e9.
700	2.	Zimmerli W. 2014. Clinical presentation and treatment of orthopaedic implant-
701		associated infection. J Intern Med.
702	3.	Moriarty TF, Kuehl R, Coenye T, Metsemakers W-JJ, Morgenstern M, Schwarz
703		EM, Riool M, Zaat SAJJ, Khana N, Kates SL, Geoff Richards R, Richards RG.
704		2016. Orthopaedic device-related infection: Current and future interventions for
705		improved prevention and treatment. EFORT Open Rev 1:89–99.
706	4.	Li B, Webster TJ. 2018. Bacteria antibiotic resistance: New challenges and
707		opportunities for implant-associated orthopedic infections. J Orthop Res 36:22-
708		32.
709	5.	PATZAKIS MJ, WILKINS J. 1989. Factors Influencing Infection Rate in Open
710		Fracture Wounds. Clin Orthop Relat Res 243.
711	6.	Boxma H, Broekhuizen T, Patka P, Oosting H. 1996. Randomised controlled
712		trial of single-dose antibiotic prophylaxis in surgical treatment of closed
713		fractures: The Dutch Trauma Trial. Lancet 347:1133–1137.
714	7.	Spiegl U, Friederichs J, Pätzold R, Militz M, Josten C, Bühren V. 2013. Risk
715		factors for failed two-stage procedure after chronic posttraumatic periprosthetic
716		hip infections. Arch Orthop Trauma Surg 133:421–428.
717	8.	Morgenstern M, Post V, Erichsen C, Hungerer S, Bühren V, Militz M, Richards
718		RG, Moriarty TF. 2016. Biofilm formation increases treatment failure in
719		Staphylococcus epidermidis device-related osteomyelitis of the lower extremity
720		in human patients. J Orthop Res 34:1905–1913.
721	9.	Guo G, Wang J, You Y, Tan J, Shen H. 2017. Distribution characteristics of
722		Staphylococcus spp. in different phases of periprosthetic joint infection: A
723		review. Exp Ther Med 13:2599.
724	10.	Teterycz D, Ferry T, Lew D, Stern R, Assal M, Hoffmeyer P, Bernard L, Uçkay
725		I. 2010. Outcome of orthopedic implant infections due to different
726		staphylococci. Int J Infect Dis 14.
727	11.	Kilgus D.J. Howe D.J. Strang A. 2002, Results of Periprosthetic Hip and Knee

11. Kilgus DJ, Howe DJ, Strang A. 2002. Results of Periprosthetic Hip and Knee

<ul> <li>Infections Caused by Resistant Bacteria. Clin Orthop Relat Res 404:116–12</li> <li>Post V, Harris LG, Morgenstern M, Mageiros L, Hitchings MD, Méric G, Pas B, Sheppard SK, Richards RG, Moriarty TF. 2017. Comparative Genomics Study of Staphylococcus epidermidis Isolates from Orthopedic-Device-Rela Infections Correlated with Patient Outcome. J Clin Microbiol 55:3089–3103.</li> <li>Arciola CR, An YH, Campoccia D, Donati ME, Montanaro L. 2005. Etiology implant orthopedic infections: A survey on 1027 clinical isolates. Int J Artif Organs 28:1091–1100.</li> <li>Campoccia D, Montanaro L, Arciola CR. 2006. The significance of infection related to orthopedic devices and issues of antibiotic resistance. Biomateria 27:2331–2339.</li> <li>Montanaro L, Ravaioli S, Ruppitsch W, Campoccia D, Pietrocola G, Visai L, Speziale P, Allerberger F, Arciola CR. 2016. Molecular characterization of a prevalent ribocluster of methicillin-sensitive Staphylococcus aureus from Orthopedic implant infections. Correspondence with MLST CC30. Front Cell Infect Microbiol 6:8.</li> <li>Otto M. 2012. Methicillin-resistant Staphylococcus aureus infection is associated with increased mortality. http://dx.doi.org/102217/fmb11156 7:18 191.</li> <li>Zhuang H, Zhu F, Lan P, Ji S, Sun L, Chen Y, Wang Z, Jiang S, Zhang L, Z Y, Jiang Y, Chen Y, Yu Y. 2021. A random forest model based on core gen allelic profiles of mrsa for penicillin plus potassium clavulanate susceptibility prodiction. Microb Conception. 7000640</li> </ul>	coe ed of
<ul> <li>B, Sheppard SK, Richards RG, Moriarty TF. 2017. Comparative Genomics</li> <li>Study of Staphylococcus epidermidis Isolates from Orthopedic-Device-Rela</li> <li>Infections Correlated with Patient Outcome. J Clin Microbiol 55:3089–3103.</li> <li>Arciola CR, An YH, Campoccia D, Donati ME, Montanaro L. 2005. Etiology</li> <li>implant orthopedic infections: A survey on 1027 clinical isolates. Int J Artif</li> <li>Organs 28:1091–1100.</li> <li>Campoccia D, Montanaro L, Arciola CR. 2006. The significance of infection</li> <li>related to orthopedic devices and issues of antibiotic resistance. Biomateria</li> <li>27:2331–2339.</li> <li>Montanaro L, Ravaioli S, Ruppitsch W, Campoccia D, Pietrocola G, Visai L,</li> <li>Speziale P, Allerberger F, Arciola CR. 2016. Molecular characterization of a</li> <li>prevalent ribocluster of methicillin-sensitive Staphylococcus aureus from</li> <li>Orthopedic implant infections. Correspondence with MLST CC30. Front Cell</li> <li>Infect Microbiol 6:8.</li> <li>Otto M. 2012. Methicillin-resistant Staphylococcus aureus infection is</li> <li>associated with increased mortality. http://dx.doi.org/102217/fmb11156 7:18</li> <li>T. Zhuang H, Zhu F, Lan P, Ji S, Sun L, Chen Y, Wang Z, Jiang S, Zhang L, Z</li> <li>Y, Jiang Y, Chen Y, Yu Y. 2021. A random forest model based on core generation</li> </ul>	ed of s
<ul> <li>Study of Staphylococcus epidermidis Isolates from Orthopedic-Device-Rela</li> <li>Infections Correlated with Patient Outcome. J Clin Microbiol 55:3089–3103.</li> <li>Arciola CR, An YH, Campoccia D, Donati ME, Montanaro L. 2005. Etiology</li> <li>implant orthopedic infections: A survey on 1027 clinical isolates. Int J Artif</li> <li>Organs 28:1091–1100.</li> <li>Campoccia D, Montanaro L, Arciola CR. 2006. The significance of infection</li> <li>related to orthopedic devices and issues of antibiotic resistance. Biomateria</li> <li>27:2331–2339.</li> <li>Montanaro L, Ravaioli S, Ruppitsch W, Campoccia D, Pietrocola G, Visai L,</li> <li>Speziale P, Allerberger F, Arciola CR. 2016. Molecular characterization of a</li> <li>prevalent ribocluster of methicillin-sensitive Staphylococcus aureus from</li> <li>Orthopedic implant infections. Correspondence with MLST CC30. Front Cell</li> <li>Infect Microbiol 6:8.</li> <li>Otto M. 2012. Methicillin-resistant Staphylococcus aureus infection is</li> <li>associated with increased mortality. http://dx.doi.org/102217/fmb11156 7:18</li> <li>17. Zhuang H, Zhu F, Lan P, Ji S, Sun L, Chen Y, Wang Z, Jiang S, Zhang L, Z</li> <li>Y, Jiang Y, Chen Y, Yu Y. 2021. A random forest model based on core generated</li> </ul>	of S
<ul> <li>Infections Correlated with Patient Outcome. J Clin Microbiol 55:3089–3103.</li> <li>Arciola CR, An YH, Campoccia D, Donati ME, Montanaro L. 2005. Etiology implant orthopedic infections: A survey on 1027 clinical isolates. Int J Artif Organs 28:1091–1100.</li> <li>Campoccia D, Montanaro L, Arciola CR. 2006. The significance of infection related to orthopedic devices and issues of antibiotic resistance. Biomateria 27:2331–2339.</li> <li>Montanaro L, Ravaioli S, Ruppitsch W, Campoccia D, Pietrocola G, Visai L, Speziale P, Allerberger F, Arciola CR. 2016. Molecular characterization of a prevalent ribocluster of methicillin-sensitive Staphylococcus aureus from Orthopedic implant infections. Correspondence with MLST CC30. Front Cell Infect Microbiol 6:8.</li> <li>Otto M. 2012. Methicillin-resistant Staphylococcus aureus infection is associated with increased mortality. http://dx.doi.org/102217/fmb11156 7:18 191.</li> <li>Zhuang H, Zhu F, Lan P, Ji S, Sun L, Chen Y, Wang Z, Jiang S, Zhang L, Z Y, Jiang Y, Chen Y, Yu Y. 2021. A random forest model based on core generated allelic profiles of mrsa for penicillin plus potassium clavulanate susceptibility</li> </ul>	of S
<ol> <li>Arciola CR, An YH, Campoccia D, Donati ME, Montanaro L. 2005. Etiology implant orthopedic infections: A survey on 1027 clinical isolates. Int J Artif Organs 28:1091–1100.</li> <li>Campoccia D, Montanaro L, Arciola CR. 2006. The significance of infection related to orthopedic devices and issues of antibiotic resistance. Biomateria 27:2331–2339.</li> <li>Montanaro L, Ravaioli S, Ruppitsch W, Campoccia D, Pietrocola G, Visai L, Speziale P, Allerberger F, Arciola CR. 2016. Molecular characterization of a prevalent ribocluster of methicillin-sensitive Staphylococcus aureus from Orthopedic implant infections. Correspondence with MLST CC30. Front Cell Infect Microbiol 6:8.</li> <li>Otto M. 2012. Methicillin-resistant Staphylococcus aureus infection is associated with increased mortality. http://dx.doi.org/102217/fmb11156 7:18 191.</li> <li>Zhuang H, Zhu F, Lan P, Ji S, Sun L, Chen Y, Wang Z, Jiang S, Zhang L, Z Y, Jiang Y, Chen Y, Yu Y. 2021. A random forest model based on core gene allelic profiles of mrsa for penicillin plus potassium clavulanate susceptibility</li> </ol>	5
<ul> <li>implant orthopedic infections: A survey on 1027 clinical isolates. Int J Artif</li> <li>Organs 28:1091–1100.</li> <li>14. Campoccia D, Montanaro L, Arciola CR. 2006. The significance of infection</li> <li>related to orthopedic devices and issues of antibiotic resistance. Biomateria</li> <li>27:2331–2339.</li> <li>15. Montanaro L, Ravaioli S, Ruppitsch W, Campoccia D, Pietrocola G, Visai L,</li> <li>Speziale P, Allerberger F, Arciola CR. 2016. Molecular characterization of a</li> <li>prevalent ribocluster of methicillin-sensitive Staphylococcus aureus from</li> <li>Orthopedic implant infections. Correspondence with MLST CC30. Front Cell</li> <li>Infect Microbiol 6:8.</li> <li>16. Otto M. 2012. Methicillin-resistant Staphylococcus aureus infection is</li> <li>associated with increased mortality. http://dx.doi.org/102217/fmb11156 7:18</li> <li>191.</li> <li>17. Zhuang H, Zhu F, Lan P, Ji S, Sun L, Chen Y, Wang Z, Jiang S, Zhang L, Z</li> <li>Y, Jiang Y, Chen Y, Yu Y. 2021. A random forest model based on core generallelic profiles of mrsa for penicillin plus potassium clavulanate susceptibility</li> </ul>	5
<ul> <li>Organs 28:1091–1100.</li> <li>14. Campoccia D, Montanaro L, Arciola CR. 2006. The significance of infection related to orthopedic devices and issues of antibiotic resistance. Biomateria 27:2331–2339.</li> <li>15. Montanaro L, Ravaioli S, Ruppitsch W, Campoccia D, Pietrocola G, Visai L, Speziale P, Allerberger F, Arciola CR. 2016. Molecular characterization of a prevalent ribocluster of methicillin-sensitive Staphylococcus aureus from Orthopedic implant infections. Correspondence with MLST CC30. Front Cell Infect Microbiol 6:8.</li> <li>16. Otto M. 2012. Methicillin-resistant Staphylococcus aureus infection is associated with increased mortality. http://dx.doi.org/102217/fmb11156 7:18 191.</li> <li>17. Zhuang H, Zhu F, Lan P, Ji S, Sun L, Chen Y, Wang Z, Jiang S, Zhang L, Z Y, Jiang Y, Chen Y, Yu Y. 2021. A random forest model based on core gene allelic profiles of mrsa for penicillin plus potassium clavulanate susceptibility</li> </ul>	
<ol> <li>Campoccia D, Montanaro L, Arciola CR. 2006. The significance of infection related to orthopedic devices and issues of antibiotic resistance. Biomateria 27:2331–2339.</li> <li>Montanaro L, Ravaioli S, Ruppitsch W, Campoccia D, Pietrocola G, Visai L, Speziale P, Allerberger F, Arciola CR. 2016. Molecular characterization of a prevalent ribocluster of methicillin-sensitive Staphylococcus aureus from Orthopedic implant infections. Correspondence with MLST CC30. Front Cell Infect Microbiol 6:8.</li> <li>Otto M. 2012. Methicillin-resistant Staphylococcus aureus infection is associated with increased mortality. http://dx.doi.org/102217/fmb11156 7:18 191.</li> <li>Zhuang H, Zhu F, Lan P, Ji S, Sun L, Chen Y, Wang Z, Jiang S, Zhang L, Z Y, Jiang Y, Chen Y, Yu Y. 2021. A random forest model based on core gene allelic profiles of mrsa for penicillin plus potassium clavulanate susceptibility</li> </ol>	
<ul> <li>related to orthopedic devices and issues of antibiotic resistance. Biomateria 27:2331–2339.</li> <li>Montanaro L, Ravaioli S, Ruppitsch W, Campoccia D, Pietrocola G, Visai L, Speziale P, Allerberger F, Arciola CR. 2016. Molecular characterization of a prevalent ribocluster of methicillin-sensitive Staphylococcus aureus from Orthopedic implant infections. Correspondence with MLST CC30. Front Cell Infect Microbiol 6:8.</li> <li>Otto M. 2012. Methicillin-resistant Staphylococcus aureus infection is associated with increased mortality. http://dx.doi.org/102217/fmb11156 7:18 191.</li> <li>Zhuang H, Zhu F, Lan P, Ji S, Sun L, Chen Y, Wang Z, Jiang S, Zhang L, Z Y, Jiang Y, Chen Y, Yu Y. 2021. A random forest model based on core generative allelic profiles of mrsa for penicillin plus potassium clavulanate susceptibility</li> </ul>	
<ul> <li>27:2331–2339.</li> <li>Montanaro L, Ravaioli S, Ruppitsch W, Campoccia D, Pietrocola G, Visai L,</li> <li>Speziale P, Allerberger F, Arciola CR. 2016. Molecular characterization of a</li> <li>prevalent ribocluster of methicillin-sensitive Staphylococcus aureus from</li> <li>Orthopedic implant infections. Correspondence with MLST CC30. Front Cell</li> <li>Infect Microbiol 6:8.</li> <li>Otto M. 2012. Methicillin-resistant Staphylococcus aureus infection is</li> <li>associated with increased mortality. http://dx.doi.org/102217/fmb11156 7:18</li> <li>191.</li> <li>Zhuang H, Zhu F, Lan P, Ji S, Sun L, Chen Y, Wang Z, Jiang S, Zhang L, Z</li> <li>Y, Jiang Y, Chen Y, Yu Y. 2021. A random forest model based on core generative</li> </ul>	
<ol> <li>Montanaro L, Ravaioli S, Ruppitsch W, Campoccia D, Pietrocola G, Visai L, Speziale P, Allerberger F, Arciola CR. 2016. Molecular characterization of a prevalent ribocluster of methicillin-sensitive Staphylococcus aureus from Orthopedic implant infections. Correspondence with MLST CC30. Front Cel Infect Microbiol 6:8.</li> <li>Otto M. 2012. Methicillin-resistant Staphylococcus aureus infection is associated with increased mortality. http://dx.doi.org/102217/fmb11156 7:18 191.</li> <li>Zhuang H, Zhu F, Lan P, Ji S, Sun L, Chen Y, Wang Z, Jiang S, Zhang L, Z Y, Jiang Y, Chen Y, Yu Y. 2021. A random forest model based on core gene allelic profiles of mrsa for penicillin plus potassium clavulanate susceptibility</li> </ol>	
<ul> <li>Speziale P, Allerberger F, Arciola CR. 2016. Molecular characterization of a</li> <li>prevalent ribocluster of methicillin-sensitive Staphylococcus aureus from</li> <li>Orthopedic implant infections. Correspondence with MLST CC30. Front Cell</li> <li>Infect Microbiol 6:8.</li> <li>Otto M. 2012. Methicillin-resistant Staphylococcus aureus infection is</li> <li>associated with increased mortality. http://dx.doi.org/102217/fmb11156 7:18</li> <li>191.</li> <li>Thuang H, Zhu F, Lan P, Ji S, Sun L, Chen Y, Wang Z, Jiang S, Zhang L, Z</li> <li>Y, Jiang Y, Chen Y, Yu Y. 2021. A random forest model based on core generated</li> <li>allelic profiles of mrsa for penicillin plus potassium clavulanate susceptibility</li> </ul>	
<ul> <li>Orthopedic implant infections. Correspondence with MLST CC30. Front Cell</li> <li>Infect Microbiol 6:8.</li> <li>Otto M. 2012. Methicillin-resistant Staphylococcus aureus infection is</li> <li>associated with increased mortality. http://dx.doi.org/102217/fmb11156 7:18</li> <li>191.</li> <li>Thuang H, Zhu F, Lan P, Ji S, Sun L, Chen Y, Wang Z, Jiang S, Zhang L, Z</li> <li>Y, Jiang Y, Chen Y, Yu Y. 2021. A random forest model based on core general</li> <li>allelic profiles of mrsa for penicillin plus potassium clavulanate susceptibility</li> </ul>	
<ul> <li>Infect Microbiol 6:8.</li> <li>Otto M. 2012. Methicillin-resistant Staphylococcus aureus infection is associated with increased mortality. http://dx.doi.org/102217/fmb11156 7:18</li> <li>191.</li> <li>Thuang H, Zhu F, Lan P, Ji S, Sun L, Chen Y, Wang Z, Jiang S, Zhang L, Z Y, Jiang Y, Chen Y, Yu Y. 2021. A random forest model based on core gene allelic profiles of mrsa for penicillin plus potassium clavulanate susceptibility</li> </ul>	
<ul> <li>744 16. Otto M. 2012. Methicillin-resistant Staphylococcus aureus infection is associated with increased mortality. http://dx.doi.org/102217/fmb11156 7:18 191.</li> <li>747 17. Zhuang H, Zhu F, Lan P, Ji S, Sun L, Chen Y, Wang Z, Jiang S, Zhang L, Z Y, Jiang Y, Chen Y, Yu Y. 2021. A random forest model based on core gene allelic profiles of mrsa for penicillin plus potassium clavulanate susceptibility</li> </ul>	
<ul> <li>associated with increased mortality. http://dx.doi.org/102217/fmb11156 7:18</li> <li>191.</li> <li>17. Zhuang H, Zhu F, Lan P, Ji S, Sun L, Chen Y, Wang Z, Jiang S, Zhang L, Z</li> <li>Y, Jiang Y, Chen Y, Yu Y. 2021. A random forest model based on core general</li> <li>allelic profiles of mrsa for penicillin plus potassium clavulanate susceptibility</li> </ul>	
<ul> <li>191.</li> <li>The angle of the second seco</li></ul>	
<ul> <li>747 17. Zhuang H, Zhu F, Lan P, Ji S, Sun L, Chen Y, Wang Z, Jiang S, Zhang L, Z</li> <li>748 Y, Jiang Y, Chen Y, Yu Y. 2021. A random forest model based on core generative</li> <li>749 allelic profiles of mrsa for penicillin plus potassium clavulanate susceptibility</li> </ul>	Э—
<ul> <li>Y, Jiang Y, Chen Y, Yu Y. 2021. A random forest model based on core generation</li> <li>allelic profiles of mrsa for penicillin plus potassium clavulanate susceptibility</li> </ul>	
allelic profiles of mrsa for penicillin plus potassium clavulanate susceptibility	iu
	me
750 prediction Microh Conomics 7:000640	
prediction. Microb Genomics 7:000610.	
751 18. Chambers HF, DeLeo FR. 2009. Waves of Resistance: Staphylococcus aur	us
in the Antibiotic Era. Nat Rev Microbiol 7:629.	
753 19. Chen H, Yin Y, van Dorp L, Shaw LP, Gao H, Acman M, Yuan J, Chen F, S	In
S, Wang X, Li S, Zhang Y, Farrer RA, Wang H, Balloux F. 2021. Drivers of	
755 methicillin-resistant Staphylococcus aureus (MRSA) lineage replacement in	
756 China. Genome Med 13:1–14.	
757 20. Harkins CP, Pichon B, Doumith M, Parkhill J, Westh H, Tomasz A, de	
<sup>758</sup> Lencastre H, Bentley SD, Kearns AM, Holden MTG. 2017. Methicillin-resist	nt
759 Staphylococcus aureus emerged long before the introduction of methicillin i	to
clinical practice. Genome Biol 18:1–11.	
21. Enright MC, Day NPJ, Davies CE, Peacock SJ, Spratt BG. 2000. Multilocus	

760		a second s
762		sequence typing for characterization of methicillin-resistant and methicillin-
763		susceptible clones of Staphylococcus aureus. J Clin Microbiol 38:1008–1015.
764	22.	Feil EJ, Cooper JE, Grundmann H, Robinson DA, Enright MC, Berendt T,
765		Peacock SJ, Smith JM, Murphy M, Spratt BG, Moore CE, Day NPJ. 2003. How
766		clonal is Staphylococcus aureus? J Bacteriol 185:3307–3316.
767	23.	Urwin R, Maiden MCJ. 2003. Multi-locus sequence typing: a tool for global
768		epidemiology. Trends Microbiol 11:479–487.
769	24.	Tenover FC, Goering R V. 2009. Methicillin-resistant Staphylococcus aureus
770		strain USA300: origin and epidemiology. J Antimicrob Chemother 64:441–446.
771	25.	Ito T, Hiramatsu K, Oliveira DC, De Lencastre H, Zhang K, Westh H, O'Brien F,
772		Giffard PM, Coleman D, Tenover FC, Boyle-Vavra S, Skov RL, Enright MC,
773		Kreiswirth B, Kwan SK, Grundmann H, Laurent F, Sollid JE, Kearns AM,
774		Goering R, John JF, Daum R, Soderquist B. 2009. Classification of
775		staphylococcal cassette chromosome mec (SCCmec): Guidelines for reporting
776		novel SCCmec elements. Antimicrob Agents Chemother 53:4961–4967.
777	26.	Strommenger B, Braulke C, Heuck D, Schmidt C, Pasemann B, Nübel U, Witte
778		W. 2008. spa Typing of Staphylococcus aureus as a Frontline Tool in
779		Epidemiological Typing. J Clin Microbiol 46:574.
780	27.	Koeck M, Como-Sabetti K, Boxrud D, Dobbins G, Glennen A, Anacker M,
781		Jawahir S, See I, Lynfield R. 2019. Burdens of Invasive Methicillin-Susceptible
782		and Methicillin-Resistant Staphylococcus aureus Disease, Minnesota, USA.
783		Emerg Infect Dis 25:171.
784	28.	David MZ, Boyle-Vavra S, Zychowski DL, Daum RS. 2011. Methicillin-
785		Susceptible Staphylococcus aureus as a Predominantly Healthcare-Associated
786		Pathogen: A Possible Reversal of Roles? PLoS One 6.
787	29.	Otto M. 2013. Community-associated MRSA: What makes them special? Int J
788		Med Microbiol 303:324–330.
789	30.	Uhlemann AC, Otto M, Lowy FD, DeLeo FR. 2014. Evolution of community-
790		and healthcare-associated methicillin-resistant Staphylococcus aureus. Infect
791		Genet Evol 21:563–574.
792	31.	Laabei M, Uhlemann AC, Lowy FD, Austin ED, Yokoyama M, Ouadi K, Feil E,
793		Thorpe HA, Williams B, Perkins M, Peacock SJ, Clarke SR, Dordel J, Holden
794		M, Votintseva AA, Bowden R, Crook DW, Young BC, Wilson DJ, Recker M,
795		Massey RC. 2015. Evolutionary Trade-Offs Underlie the Multi-faceted

796		Virulence of Staphylococcus aureus. PLOS Biol 13:e1002229.
797	32.	Sheppard SK. 2022. Strain wars and the evolution of opportunistic pathogens.
798		Curr Opin Microbiol 67.
799	33.	Otto M. 2012. MRSA virulence and spread. Cell Microbiol 14:1513–1521.
800	34.	Otto M. 2010. Basis of virulence in community-associated methicillin-resistant
801		Staphylococcus aureus. Annu Rev Microbiol 64:143–162.
802	35.	Archer GL. 1998. Staphylococcus aureus: a well-armed pathogen. Clin Infect
803		Dis 26:1179–1181.
804	36.	Arciola CR, Visai L, Testoni F, Arciola S, Campoccia D, Speziale P, Montanaro
805		L. 2011. Concise survey of Staphylococcus aureus virulence factors that
806		promote adhesion and damage to peri-implant tissues. Int J Artif Organs
807		34:771–780.
808	37.	Lina G, Quaglia A, Reverdy ME, Leclercq R, Vandenesch F, Etienne J. 1999.
809		Distribution of genes encoding resistance to macrolides, lincosamides, and
810		streptogramins among staphylococci. Antimicrob Agents Chemother 43:1062-
811		1066.
812	38.	Mehrotra M, Wang G, Johnson WM. 2000. Multiplex PCR for detection of
813		genes for Staphylococcus aureus enterotoxins, exfoliative toxins, toxic shock
814		syndrome toxin 1, and methicillin resistance. J Clin Microbiol 38:1032–1035.
815	39.	Kobras CM, Fenton AK, Sheppard SK. 2021. Next-generation microbiology:
816		from comparative genomics to gene function. Genome Biol 2021 221 22:1–16.
817	40.	Sheppard SK, Guttman DS, Fitzgerald JR. 2018. Population genomics of
818		bacterial host adaptation. Nat Rev Genet 2018 199 19:549–565.
819	41.	Méric G, Yahara K, Mageiros L, Pascoe B, Maiden MCJ, Jolley KA, Sheppard
820		SK. 2014. A reference pan-genome approach to comparative bacterial
821		genomics: Identification of novel epidemiological markers in pathogenic
822		Campylobacter. PLoS One 9.
823	42.	Recker M, Laabei M, Toleman MS, Reuter S, Saunderson RB, Blane B, Török
824		ME, Ouadi K, Stevens E, Yokoyama M, Steventon J, Thompson L, Milne G,
825		Bayliss S, Bacon L, Peacock SJ, Massey RC. 2017. Clonal differences in
826		Staphylococcus aureus bacteraemia-associated mortality. Nat Microbiol
827		2:1381–1388.
828	43.	Meric G, Mageiros L, Pensar J, Laabei M, Yahara K, Pascoe B, Kittiwan N,
829		Tadee P, Post V, Lamble S, Bowden R, Bray JE, Morgenstern M, Jolley KA,

830		Maiden MCJ, Feil EJ, Didelot X, Miragaia M, de Lencastre H, Moriarty TF,
831		Rohde H, Massey RC, Mack D, Corander J, Sheppard SK. 2018. Disease-
832		associated genotypes of the commensal skin bacterium Staphylococcus
833		epidermidis. Nat Commun 9.
834	44.	Laabei M, Recker M, Rudkin JK, Aldeljawi M, Gulay Z, Sloan TJ, Williams P,
835		Endres JL, Bayles KW, Fey PD, Yajjala VK, Widhelm T, Hawkins E, Lewis K,
836		Parfett S, Scowen L, Peacock SJ, Holden M, Wilson D, Read TD, Van Den
837		Elsen J, Priest NK, Feil EJ, Hurst LD, Josefsson E, Massey RC. 2014.
838		Predicting the virulence of MRSA from its genome sequence. Genome Res
839		24:839–849.
840	45.	Gordon NC, Price JR, Cole K, Everitt R, Morgan M, Finney J, Kearns AM,
841		Pichon B, Young B, Wilson DJ, Llewelyn MJ, Paul J, Peto TEA, Crook DW,
842		Walker AS, Golubchik T. 2014. Prediction of staphylococcus aureus
843		antimicrobial resistance by whole-genome sequencing. J Clin Microbiol
844		52:1182–1191.
845	46.	Berthenet E, Yahara K, Thorell K, Pascoe B, Meric G, Mikhail JM, Engstrand L,
846		Enroth H, Burette A, Megraud F, Varon C, Atherton JC, Smith S, Wilkinson TS,
847		Hitchings MD, Falush D, Sheppard SK. 2018. A GWAS on Helicobacter pylori
848		strains points to genetic variants associated with gastric cancer risk. BMC Biol
849		https://doi.org/10.1186/s12915-018-0550-3.
850	47.	Hwang W, Yong JH, Min KB, Lee KM, Pascoe B, Sheppard SK, Yoon SS.
851		2021. Genome-wide association study of signature genetic alterations among
852		pseudomonas aeruginosa cystic fibrosis isolates. PLoS Pathog 17.
853	48.	Peters S, Pascoe B, Wu Z, Bayliss SC, Zeng X, Edwinson A, Veerabadhran-
854		Gurunathan S, Jawahir S, Calland JK, Mourkas E, Patel R, Wiens T, Decuir M,
855		Boxrud D, Smith K, Parker CT, Farrugia G, Zhang Q, Sheppard SK, Grover M.
856		2021. Campylobacter jejuni genotypes are associated with post-infection
857		irritable bowel syndrome in humans. Commun Biol 4.
858	49.	Sassi M, Bronsard J, Pascreau G, Emily M, Donnio P-Y, Revest M, Felden B,
859		Wirth T, Augagneur Y. 2022. Forecasting Staphylococcus aureus Infections
860		Using Genome-Wide Association Studies, Machine Learning, and
861		Transcriptomic Approaches. mSystems
862		https://doi.org/10.1128/MSYSTEMS.00378-22.
863	50.	Aanensen DM, Feil EJ, Holden MTG, Dordel J, Yeats CA, Fedosejev A, Goater

864		R, Castillo-Ramírez S, Corander J, Colijn C, Chlebowicz MA, Schouls L, Heck
865		M, Pluister G, Ruimy R, Kahlmeter G, Åhman J, Matuschek E, Friedrich AW,
866		Parkhill J, Bentley SD, Spratt BG, Grundmannj H, Krziwanek K, Stumvoll S,
867		Koller W, Denis O, Struelens M, Nashev D, Budimir A, Kalenic S, Pieridou-
868		Bagatzouni D, Jakubu V, Zemlickova H, Westh H, Larsen AR, Skov R, Laurent
869		F, Ettienne J, Strommenger B, Witte W, Vourli S, Vatopoulos A, Vainio A,
870		Vuopio-Varkila J, Fuzi M, Ungvári E, Murchan S, Rossney A, Miklasevics E,
871		Balode A, Haraldsson G, Kristinsson KG, Monaco M, Pantosti A, Borg M, Van
872		Santen-Verheuvel M, Huijsdens X, Marstein L, Jacobsen T, Simonsen GS,
873		Airesde-Sousa M, De Lencastre H, Luczak-Kadlubowska A, Hryniewicz W,
874		Straut M, Codita I, Perez-Vazquez M, Iglesias JO, Spik VC, Mueller-Premru M,
875		Haeggman S, Olsson-Liljequist B, Ellington M, Kearns A. 2016. Whole-genome
876		sequencing for routine pathogen surveillance in public health: A population
877		snapshot of invasive Staphylococcus aureus in Europe. MBio 7.
878	51.	Garvey MI, Bradley CW, Holden KL, Oppenheim B. 2017. Outbreak of clonal
879		complex 22 Panton-Valentine leucocidin-positive methicillin-resistant
880		Staphylococcus aureus. J Infect Prev 18:224–230.
881	52.	de Vos AS, de Vlas SJ, Lindsay JA, Kretzschmar MEE, Knight GM. 2021.
882		Understanding MRSA clonal competition within a UK hospital; the possible
883		importance of density dependence. Epidemics 37:100511.
884	53.	SC B, HA T, NM C, SK S, EJ F. 2019. PIRATE: A fast and scalable
885		pangenomics toolbox for clustering diverged orthologues in bacteria.
886		Gigascience 8.
887	54.	Méric G, Miragaia M, De Been M, Yahara K, Pascoe B, Mageiros L, Mikhail J,
888		Harris LG, Wilkinson TS, Rolo J, Lamble S, Bray JE, Jolley KA, Hanage WP,
889		Bowden R, Maiden MCJ, Mack D, De Lencastre H, Feil EJ, Corander J,
890		Sheppard SK. 2015. Ecological overlap and horizontal gene transfer in
891		Staphylococcus aureus and Staphylococcus epidermidis. Genome Biol Evol 7.
892	55.	Manara S, Pasolli E, Dolce D, Ravenni N, Campana S, Armanini F, Asnicar F,
893		Mengoni A, Galli L, Montagnani C, Venturini E, Rota-Stabelli O, Grandi G,
894		Taccetti G, Segata N. 2018. Whole-genome epidemiology, characterisation,
895		and phylogenetic reconstruction of Staphylococcus aureus strains in a
896		paediatric hospital. Genome Med 2018 101 10:1–19.
897	56.	Moller AG, Robert A. Petit I, Read TD. 2022. Species-Scale Genomic Analysis

898		of Staphylococcus aureus Genes Influencing Phage Host Range and Their
899		Relationships to Virulence and Antibiotic Resistance Genes. mSystems 7.
900	57.	Suzuki H, Lefébure T, Bitar PP, Stanhope MJ. 2012. Comparative genomic
901		analysis of the genus Staphylococcus including Staphylococcus aureus and its
902		newly described sister species Staphylococcus simiae. BMC Genomics 13:38.
903	58.	Hadfield J, Croucher NJ, Goater RJ, Abudahab K, Aanensen DM, Harris SR.
904		2018. Phandango: An interactive viewer for bacterial population genomics.
905		Bioinformatics https://doi.org/10.1093/bioinformatics/btx610.
906	59.	Lees JA, Harris SR, Tonkin-Hill G, Gladstone RA, Lo SW, Weiser JN, Corander
907		J, Bentley SD, Croucher NJ. 2019. Fast and flexible bacterial genomic
908		epidemiology with PopPUNK. Genome Res 29:304–316.
909	60.	Brynildsrud O, Bohlin J, Scheffer L, Eldholm V. 2016. Rapid scoring of genes in
910		microbial pan-genome-wide association studies with Scoary. Genome Biol
911		17:238.
912	61.	Anderson KL, Roberts C, Disz T, Vonstein V, Hwang K, Overbeek R, Olson
913		PD, Projan SJ, Dunman PM. 2006. Characterization of the Staphylococcus
914		aureus Heat Shock, Cold Shock, Stringent, and SOS Responses and Their
915		Effects on Log-Phase mRNA Turnover. J Bacteriol 188:6739.
916	62.	C BG, Sahukhal GS, Elasri MO. 2022. Delineating the Role of the msaABCR
917		Operon in Staphylococcal Overflow Metabolism. Front Microbiol 13:914512.
918	63.	Sahukhal GS, Elasri MO. 2014. Identification and characterization of an
919		operon, msaABCR, that controls virulence and biofilm development in
920		Staphylococcus aureus. BMC Microbiol 14:154.
921	64.	Pandey S, Sahukhal GS, Elasri MO. 2021. The msaABCR Operon Regulates
922		Persister Formation by Modulating Energy Metabolism in Staphylococcus
923		aureus. Front Microbiol 12:881.
924	65.	Murray S, Pascoe B, Méric G, Mageiros L, Yahara K, Hitchings MD, Friedmann
925		Y, Wilkinson TS, Gormley FJ, Mack D, Bray JE, Lamble S, Bowden R, Jolley
926		KA, Maiden MCJ, Wendlandt S, Schwarz S, Corander J, Fitzgerald JR,
927		Sheppard SK. 2017. Recombination-Mediated Host Adaptation by Avian
928		Staphylococcus aureus. Genome Biol Evol 9:830–842.
929	66.	Lowder B V., Guinane CM, Zakour NLB, Weinert LA, Conway-Morris A,
930		Cartwright RA, Simpson AJ, Rambaut A, Nübel U, Fitzgerald JR. 2009. Recent
931		human-to-poultry host jump, adaptation, and pandemic spread of

932		Staphylococcus aureus. Proc Natl Acad Sci U S A 106:19545–19550.
933	67.	Jian Y, Zhao L, Zhao N, Lv HY, Liu Y, He L, Liu Q, Li M. 2021. Increasing
934		prevalence of hypervirulent ST5 methicillin susceptible Staphylococcus aureus
935		subtype poses a serious clinical threat. Emerg Microbes Infect 10:109.
936	68.	Nübel U, Roumagnac P, Feldkamp M, Song JH, Ko KS, Huang YC, Coombs G,
937		Ip M, Westh H, Skov R, Struelens MJ, Goering R V., Strommenger B, Weller A,
938		Witte W, Achtman M. 2008. Frequent emergence and limited geographic
939		dispersal of methicillin-resistant Staphylococcus aureus. Proc Natl Acad Sci U
940		S A 105:14130–14135.
941	69.	Bal AM, Coombs GW, Holden MTG, Lindsay JA, Nimmo GR, Tattevin P, Skov
942		RL. 2016. Genomic insights into the emergence and spread of international
943		clones of healthcare-, community- and livestock-associated meticillin-resistant
944		Staphylococcus aureus: Blurring of the traditional definitions. J Glob Antimicrob
945		Resist 6:95–101.
946	70.	Hsu LY, Harris SR, Chlebowicz MA, Lindsay JA, Koh TH, Krishnan P, Tan TY,
947		Hon PY, Grubb WB, Bentley SD, Parkhill J, Peacock SJ, Holden MTG. 2015.
948		Evolutionary dynamics of methicillin-resistant Staphylococcus aureus within a
949		healthcare system. Genome Biol 16:1–13.
950	71.	Kong EF, Johnson JK, Jabra-Rizk MA. 2016. Community-Associated
951		Methicillin-Resistant Staphylococcus aureus: An Enemy amidst Us. PLOS
952		Pathog 12:e1005837.
953	72.	Strauß L, Stegger M, Akpaka PE, Alabi A, Breurec S, Coombs G, Egyir B,
954		Larsen AR, Laurent F, Monecke S, Peters G, Skov R, Strommenger B,
955		Vandenesch F, Schaumburg F, Mellmann A. Origin, evolution, and global
956		transmission of community-acquired Staphylococcus aureus ST8
957		https://doi.org/10.1073/pnas.1702472114.
958	73.	Wyllie DH, Walker AS, Miller R, Moore C, Williamson SR, Schlackow I, Finney
959		JM, O'Connor L, Peto TEA, Crook DW. 2011. Decline of meticillin-resistant
960		Staphylococcus aureus in Oxfordshire hospitals is strain-specific and preceded
961		infection-control intensification. BMJ Open 1:e000160.
962	74.	Holden MTG, Hsu LY, Kurt K, Weinert LA, Mather AE, Harris SR, Strommenger
963		B, Layer F, Witte W, De Lencastre H, Skov R, Westh H, Žemličková H,
964		Coombs G, Kearns AM, Hill RLR, Edgeworth J, Gould I, Gant V, Cooke J,
965		Edwards GF, McAdam PR, Templeton KE, McCann A, Zhou Z, Castillo-

966		Ramírez S, Feil EJ, Hudson LO, Enright MC, Balloux F, Aanensen DM, Spratt
967		BG, Fitzgerald JR, Parkhill J, Achtman M, Bentley SD, Nübel U. 2013. A
968		genomic portrait of the emergence, evolution, and global spread of a
969		methicillin-resistant Staphylococcus aureus pandemic. Genome Res 23:653-
970		664.
971	75.	Aires-de-Sousa M, Correia B, De Lencastre H, Alves V, Branca F, Cabral L,
972		Clemente J, Daniel I, Faustino A, Ferreira E, Lameiras C, Lopes J, Marques J,
973		Peres I, Ribeiro G, Sancho L, Santos O, Santos P, Vaz MT, Videira Z. 2008.
974		Changing patterns in frequency of recovery of five methicillin-resistant
975		Staphylococcus aureus clones in Portuguese hospitals: Surveillance over a 16-
976		year period. J Clin Microbiol 46:2912–2917.
977	76.	Gill JL, Hedge J, Wilson DJ, MacLean RC. 2021. Evolutionary Processes
978		Driving the Rise and Fall of Staphylococcus aureus ST239, a Dominant Hybrid
979		Pathogen. MBio https://doi.org/10.1128/MBIO.02168-21.
980	77.	Wang M, Zheng Y, Mediavilla JR, Chen L, Kreiswirth BN, Song Y, Yang R, Du
981		H. 2017. Hospital Dissemination of tst-1-Positive Clonal Complex 5 (CC5)
982		Methicillin-Resistant Staphylococcus aureus. Front Cell Infect Microbiol 7.
983	78.	Goudarzi M, Razeghi M, Chirani AS, Fazeli M, Tayebi Z, Pouriran R. 2020.
984		Characteristics of methicillin-resistant Staphylococcus aureus carrying the toxic
985		shock syndrome toxin gene: high prevalence of clonal complex 22 strains and
986		the emergence of new spa types t223 and t605 in Iran. New Microbes New
987		Infect 36:100695.
988	79.	Brescó MS, Harris LG, Thompson K, Stanic B, Morgenstern M, O'Mahony L,
989		Richards RG, Moriarty TF. 2017. Pathogenic mechanisms and host interactions
990		in Staphylococcus epidermidis device-related infection. Front Microbiol 8:1401.
991	80.	Fey PD, Olson ME. 2010. Current concepts in biofilm formation of
992		Staphylococcus epidermidis. Future Microbiol 5:917.
993	81.	Mack D. 1999. Molecular mechanisms of Staphylococcus epidermidis biofilm
994		formation. J Hosp Infect 43:S113–S125.
995	82.	Harris LG, Murray S, Pascoe B, Bray J, Meric G, Magerios L, Wilkinson TS,
996		Jeeves R, Rohde H, Schwarz S, De Lencastre H, Miragaia M, Rolo J, Bowden
997		R, Jolley KA, Maiden MCJ, Mack D, Sheppard SK. 2016. Biofilm Morphotypes
998		and Population Structure among Staphylococcus epidermidis from Commensal
999		and Clinical Samples. PLoS One 11.

1000	83.	Clauditz A, Resch A, Wieland KP, Peschel A, Götz F. 2006. Staphyloxanthin
1001		Plays a Role in the Fitness of Staphylococcus aureus and Its Ability To Cope
1002		with Oxidative Stress. Infect Immun 74:4950.
1003	84.	Xue L, Chen YY, Yan Z, Lu W, Wan D, Zhu H. 2019. Staphyloxanthin: a
1004		potential target for antivirulence therapy. Infect Drug Resist 12:2151.
1005	85.	Post V, Wahl P, Uçkay I, Ochsner P, Zimmerli W, Corvec S, Loiez C, Richards
1006		RG, Moriarty TF. 2014. Phenotypic and genotypic characterisation of
1007		Staphylococcus aureus causing musculoskeletal infections. Int J Med Microbiol
1008		304:565–576.
1009	86.	Rooijakkers SHM, Ruyken M, van Roon J, van Kessel KPM, van Strijp JAG,
1010		van Wamel WJB. 2006. Early expression of SCIN and CHIPS drives instant
1011		immune evasion by Staphylococcus aureus. Cell Microbiol 8:1282–1293.
1012	87.	De Haas CJC, Veldkamp KE, Peschel A, Weerkamp F, Van Wamel WJB,
1013		Heezius ECJM, Poppelier MJJG, Van Kessel KPM, Van Strijp JAG. 2004.
1014		Chemotaxis Inhibitory Protein of Staphylococcus aureus, a Bacterial
1015		Antiinflammatory Agent. J Exp Med 199:687.
1016	88.	Uçkay I, Teterycz D, Ferry T, Harbarth S, Lübbeke A, Emonet S, Chilcott M,
1017		Hoffmeyer P, Bernard L. 2009. Poor utility of MRSA screening to predict
1018		staphylococcal species in orthopaedic implant infections. J Hosp Infect 73:89-
1019		91.
1020	89.	Ferry T, Uçkay I, Vaudaux P, François P, Schrenzel J, Harbarth S, Laurent F,
1021		Bernard L, Vandenesch F, Etienne J, Hoffmeyer P, Lew D. 2010. Risk factors
1022		for treatment failure in orthopedic device-related methicillin-resistant
1023		Staphylococcus aureus infection. Eur J Clin Microbiol Infect Dis 29:171–180.
1024	90.	Young BC, Wu C-H, Charlesworth J, Earle S, Price JR, Gordon NC, Cole K,
1025		Dunn L, Liu E, Oakley S, Godwin H, Fung R, Miller R, Knox K, Votintseva A,
1026		Quan TP, Tilley R, Scarborough M, Crook DW, Peto TE, Walker AS, Llewelyn
1027		MJ, Wilson DJ. 2021. Antimicrobial resistance determinants are associated
1028		with Staphylococcus aureus bacteraemia and adaptation to the healthcare
1029		environment: a bacterial genome-wide association study. Microb Genomics
1030		7:700.
1031	91.	Castillo-Ramírez S, Corander J, Marttinen P, Aldeljawi M, Hanage WP, Westh
1032		H, Boye K, Gulay Z, Bentley SD, Parkhill J, Holden MT, Feil EJ. 2012.
1033		Phylogeographic variation in recombination rates within a global clone of


1034		methicillin-resistant Staphylococcus aureus. Genome Biol 13:1–13.
1035	92.	Earle SG, Wu C-H, Charlesworth J, Stoesser N, Gordon NC, Walker TM,
1036		Spencer CCA, Iqbal Z, Clifton DA, Hopkins KL, Woodford N, Smith EG, Ismail
1037		N, Llewelyn MJ, Peto TE, Crook DW, McVean G, Walker AS, Wilson DJ. 2016.
1038		Identifying lineage effects when controlling for population structure improves
1039		power in bacterial association studies. Nat Microbiol 1:16041.
1040	93.	Collins C, Didelot X. 2018. A phylogenetic method to perform genome-wide
1041		association studies in microbes that accounts for population structure and
1042		recombination. PLoS Comput Biol 14.
1043	94.	Taylor AJ, Méric G, Yahara K, Pascoe B, Mageiros L, Mourkas E, Calland JK,
1044		Puranen S, Hitchings MD, Jolley KA, Kobras CM, Williams NJ, Vliet AHM van,
1045		Parkhill J, Maiden MCJ, Corander J, Hurst LD, Falush D, Didelot X, Kelly DJ,
1046		Sheppard SK. 2022. A two-hit epistasis model prevents core genome
1047		disharmony in recombining bacteria. bioRxiv 2021.03.15.435406.
1048	95.	Yokoyama M, Stevens E, Laabei M, Bacon L, Heesom K, Bayliss S, Ooi N,
1049		O'Neill AJ, Murray E, Williams P, Lubben A, Reeksting S, Meric G, Pascoe B,
1050		Sheppard SK, Recker M, Hurst LD, Massey RC. 2018. Epistasis analysis
1051		uncovers hidden antibiotic resistance-associated fitness costs hampering the
1052		evolution of MRSA. Genome Biol 19.
1053	96.	Paterson GK, Harrison EM, Murray GGR, Welch JJ, Warland JH, Holden MTG,
1054		Morgan FJE, Ba X, Koop G, Harris SR, Maskell DJ, Peacock SJ, Herrtage ME,
1055		Parkhill J, Holmes MA. 2015. Capturing the cloud of diversity reveals
1056		complexity and heterogeneity of MRSA carriage, infection and transmission.
1057		Nat Commun 2015 61 6:1–10.
1058	97.	Didelot X, Walker AS, Peto TE, Crook DW, Wilson DJ. 2016. Within-host
1059		evolution of bacterial pathogens. Nat Rev Microbiol. Nature Publishing Group.
1060	98.	Golubchik T, Batty EM, Miller RR, Farr H, Young BC, Larner-Svensson H, Fung
1061		R, Godwin H, Knox K, Votintseva A, Everitt RG, Street T, Cule M, Ip CLC,
1062		Didelot X, Peto TEA, Harding RM, Wilson DJ, Crook DW, Bowden R. 2013.
1063		Within-Host Evolution of Staphylococcus aureus during Asymptomatic
1064		Carriage. PLoS One 8.
1065	99.	Young BC, Golubchik T, Batty EM, Fung R, Larner-Svensson H, Votintseva
1066		AA, Miller RR, Godwin H, Knox K, Everitt RG, Iqbal Z, Rimmer AJ, Cule M, Ip
1067		CLC, Didelot X, Harding RM, Donnelly P, Peto TE, Crook DW, Bowden R,


1068		Wilsona DJ. 2012. Evolutionary dynamics of Staphylococcus aureus during
1069		progression from carriage to disease. Proc Natl Acad Sci 109:4550–4555.
1070	100.	Kahl BC. 2014. Small colony variants (SCVs) of Staphylococcus aureus – A
1071		bacterial survival strategy. Infect Genet Evol 21:515–522.
1072	101.	Loss G, Simões PM, Valour F, Cortês MF, Gonzaga L, Bergot M, Trouillet-
1073		Assant S, Josse J, Diot A, Ricci E, Vasconcelos AT, Laurent F. 2019.
1074		Staphylococcus aureus Small Colony Variants (SCVs): News From a Chronic
1075		Prosthetic Joint Infection. Front Cell Infect Microbiol 9:363.
1076	102.	Peyrusson F, Varet H, Nguyen TK, Legendre R, Sismeiro O, Coppée JY, Wolz
1077		C, Tenson T, Van Bambeke F. 2020. Intracellular Staphylococcus aureus
1078		persisters upon antibiotic exposure. Nat Commun 2020 111 11:1–14.
1079	103.	Lechner S, Lewis K, Bertram R. 2012. Staphylococcus aureus Persisters
1080		Tolerant to Bactericidal Antibiotics. Microb Physiol 22:235–244.
1081	104.	Pascoe B, Dams L, Wilkinson TS, Harris LG, Bodger O, Mack D, Davies AP.
1082		2014. Dormant cells of Staphylococcus aureus are resuscitated by spent
1083		culture supernatant. PLoS One 9.
1084	105.	Conlon BP, Rowe SE, Gandt AB, Nuxoll AS, Donegan NP, Zalis EA, Clair G,
1085		Adkins JN, Cheung AL, Lewis K. 2016. Persister formation in Staphylococcus
1086		aureus is associated with ATP depletion. Nat Microbiol 1.
1087	106.	Bankevich A, Nurk S, Antipov D, Gurevich AA, Dvorkin M, Kulikov AS, Lesin
1088		VM, Nikolenko SI, Pham S, Prjibelski AD, Pyshkin A V., Sirotkin A V., Vyahhi
1089		N, Tesler G, Alekseyev MA, Pevzner PA. 2012. SPAdes: A New Genome
1090		Assembly Algorithm and Its Applications to Single-Cell Sequencing. J Comput
1091		Biol 19:455–477.
1092	107.	Katoh K, Standley DM. 2013. MAFFT Multiple Sequence Alignment Software
1093		Version 7: Improvements in Performance and Usability. Mol Biol Evol 30:772–
1094		780.
1095	108.	Nguyen L-T, Schmidt HA, von Haeseler A, Minh BQ. 2015. IQ-TREE: A Fast
1096		and Effective Stochastic Algorithm for Estimating Maximum-Likelihood
1097		Phylogenies. Mol Biol Evol 32:268–274.
1098	109.	Hoang DT, Chernomor O, von Haeseler A, Minh BQ, Vinh LS. 2018. UFBoot2:
1099		Improving the Ultrafast Bootstrap Approximation. Mol Biol Evol 35:518–522.
1100	110.	Argimón S, Abudahab K, Goater RJE, Fedosejev A, Bhai J, Glasner C, Feil EJ,
1101		Holden MTG, Yeats CA, Grundmann H, Spratt BG, Aanensen DM. 2016.


1102		Microreact: visualizing and sharing data for genomic epidemiology and
1103		phylogeography. Microb Genomics 2.
1104	111.	Jolley KA, Bray JE, Maiden MCJ. 2018. Open-access bacterial population
1105		genomics: BIGSdb software, the PubMLST.org website and their applications.
1106		Wellcome open Res 3.
1107	112.	Petit RA, Read TD. 2018. Staphylococcus aureus viewed from the perspective
1108		of 40,000+ genomes. PeerJ 2018:e5261.
1109	113.	Bartels MD, Petersen A, Worning P, Nielsen JB, Larner-Svensson H, Johansen
1110		HK, Andersen LP, Jarløv JO, Boye K, Larsen AR, Westh H. 2014. Comparing
1111		Whole-Genome Sequencing with Sanger Sequencing for spa Typing of
1112		Methicillin-Resistant Staphylococcus aureus. J Clin Microbiol 52:4305.
1113	114.	Chen L, Zheng D, Liu B, Yang J, Jin Q. 2016. VFDB 2016: Hierarchical and
1114		refined dataset for big data analysis - 10 years on. Nucleic Acids Res 44:D694-
1115		D697.
1116	115.	Feldgarden M, Brover V, Haft DH, Prasad AB, Slotta DJ, Tolstoy I, Tyson GH,
1117		Zhao S, Hsu C-H, McDermott PF, Tadesse DA, Morales C, Simmons M,
1118		Tillman G, Wasilenko J, Folster JP, Klimke W. 2019. Using the NCBI
1119		AMRFinder Tool to Determine Antimicrobial Resistance Genotype-Phenotype
1120		Correlations Within a Collection of NARMS Isolates. bioRxiv 550707.
1121	116.	Alcock BP, Raphenya AR, Lau TTY, Tsang KK, Bouchard M, Edalatmand A,
1122		Huynh W, Nguyen A-L V, Cheng AA, Liu S, Min SY, Miroshnichenko A, Tran H-
1123		K, Werfalli RE, Nasir JA, Oloni M, Speicher DJ, Florescu A, Singh B, Faltyn M,
1124		Hernandez-Koutoucheva A, Sharma AN, Bordeleau E, Pawlowski AC, Zubyk
1125		HL, Dooley D, Griffiths E, Maguire F, Winsor GL, Beiko RG, Brinkman FSL,
1126		Hsiao WWL, Domselaar G V, McArthur AG. 2019. CARD 2020: antibiotic
1127		resistome surveillance with the comprehensive antibiotic resistance database.
1128		Nucleic Acids Res https://doi.org/10.1093/nar/gkz935.
1129	117.	Altschul SF, Gish W, Miller W, Myers EW, Lipman DJ. 1990. Basic local
1130		alignment search tool. J Mol Biol 215:403–410.
1131	118.	EFSA/ECDC. 2019. European Food Safety Authority and European Centre for
1132		Disease Prevention and Control. The European Union summary report on
1133		antimicrobial resistance in zoonotic and indicator bacteria from humans,
1134		animals and food in 2017. EFSA J 17:5598.
1135	119.	Herbert S, Ziebandt AK, Ohlsen K, Schäfer T, Hecker M, Albrecht D, Novick R,


1136		Götz F. 2010. Repair of Global Regulators in Staphylococcus aureus 8325 and
1137		Comparative Analysis with Other Clinical Isolates. Infect Immun 78:2877.
1138	120.	Stepanović S, Vuković D, Hola V, Di Bonaventura G, Djukić S, Ćirković I,
1139		Ruzicka F. 2007. Quantification of biofilm in microtiter plates: overview of
1140		testing conditions and practical recommendations for assessment of biofilm
1141		production by staphylococci. APMIS 115:891–899.
1142	121.	Ignasiak K, Maxwell A. 2017. Galleria mellonella (greater wax moth) larvae as
1143		a model for antibiotic susceptibility testing and acute toxicity trials. BMC Res
1144		Notes 10:428.
1145	122.	Desbois AP, Coote PJ. 2011. Wax moth larva (Galleria mellonella): an in vivo
1146		model for assessing the efficacy of antistaphylococcal agents. J Antimicrob
1147		Chemother 66:1785–1790.
1148	123.	Croucher NJ, Page AJ, Connor TR, Delaney AJ, Keane JA, Bentley SD,
1149		Parkhill J, Harris SR. 2015. Rapid phylogenetic analysis of large samples of
1150		recombinant bacterial whole genome sequences using Gubbins. Nucleic Acids
1151		Res 43:e15–e15.
1152	124.	Mageiros L, Méric G, Bayliss SC, Pensar J, Pascoe B, Mourkas E, Calland JK,
1153		Yahara K, Murray S, Wilkinson TS, Williams LK, Hitchings MD, Porter J,
1154		Kemmett K, Feil EJ, Jolley KA, Williams NJ, Corander J, Sheppard SK. 2021.
1155		Genome evolution and the emergence of pathogenicity in avian Escherichia
1156		coli. Nat Commun 12.
1157	125.	Mourkas E, Florez-Cuadrado D, Pascoe B, Calland JK, Bayliss SC, Mageiros
1158		L, Méric G, Hitchings MD, Quesada A, Porrero C, Ugarte-Ruiz M, Gutiérrez-
1159		Fernández J, Domínguez L, Sheppard SK. 2019. Gene pool transmission of
1160		multidrug resistance among Campylobacter from livestock, sewage and human
1161		disease. Environ Microbiol https://doi.org/10.1111/1462-2920.14760.
1162	126.	Schliep KP. 2011. phangorn: phylogenetic analysis in R. Bioinformatics
1163		27:592–593.
1164	127.	Connor TR, Loman NJ, Thompson S, Smith A, Southgate J, Poplawski R, Bull
1165		MJ, Richardson E, Ismail M, Thompson SE-, Kitchen C, Guest M, Bakke M,
1166		Sheppard SK, Pallen MJ. 2016. CLIMB (the Cloud Infrastructure for Microbial
1167		Bioinformatics): an online resource for the medical microbiology community.
1168		Microb Genomics 2.
1169	128.	Grüning B, Dale R, Sjödin A, Chapman BA, Rowe J, Tomkins-Tinch CH,

- 1170 Valieris R, Köster J. 2018. Bioconda: sustainable and comprehensive software
- distribution for the life sciences. Nat Methods 15:475–476.
- 1172 129. Jolley KA, Maiden MCJ. 2010. BIGSdb: Scalable analysis of bacterial genome
- variation at the population level. BMC Bioinformatics 11:595.
- 1174
- 1175












Table 1: Cohort description

	Compl cohort	ete study
Total, n (%)	86	(100%)
Clinical course and infection outcome, n (%)		
Multiple revision surgeries	83	96.5%
Cured	65	75.6%
Health status, n (%)		
Obesity	25	29.1%
Smoking	28	32.6%
Diabetes	16	18.6%
Chronic immunosuppression	11	12.8%
Infection characteristics, n (%)		
Peri-prosthetic joint infection	19	22.1%
Acute infection	25	29.1%
Open fracture (initially)	21	24.4%
Type of implant, n (%)		
Peri-prosthetic joint infection (PJI)	19	22.1%
Nail	19	22.1%
Plate	36	41.9%
Screw	6	7.0%
Fixateur externe	4	4.7%
K-wire	1	1.2%
Ligament reconstruction device	1	1.2%

### Table 2: Patient risk factors

		Cured outcome				
Prognostic factor	_	No		Yes		p-value
		n=	(%)	n=	(%)	
Total		21	24.4%	65	75.6%	
Obesity						0.295
-	No	13	21.3%	48	78.7%	
	Yes	8	32.0%	17	68.0%	
Smoking						0.931
-	No	14	24.1%	44	75.9%	
	Yes	7	25.0%	21	75.0%	
Diabetes mellitus						0.559
	No	18	25.7%	52	74.3%	
	Yes	3	18.8%	13	81.3%	
Chronic immunosupression						0.606
-	No	19	25.3%	56	74.7%	
	Yes	2	18.2%	9	81.8%	
Open fracture (initially)						0.510
	No	17	26.2%	48	73.8%	
	Yes	4	19.0%	17	81.0%	
Acute infection						0.541
	No	16	26.2%	45	73.8%	
	Yes	5	20.0%	20	80.0%	
Multiple revision surgeries						0.316
	No	0	0.0%	3	100.0%	
	Yes	21	25.3%	62	74.7%	

#### Table 3: Phenotypic risk factors

		Cured outcome					
S. aureus phenotype	_	No		Yes		p-value	
		n=	(%)	n=	(%)		
Total	· · ·	21	24.4%	65	75.6%		
Biofilm formation						0.429	
	No	14	27.5%	37	72.5%		
	Yes	7	20.0%	28	80.0%		
Staphyloxanthin production						0.976	
	No	8	24.2%	25	75.8%		
	Yes	13	24.5%	40	75.5%		
Hemolysis activity						0.090	**
	No	16	30.8%	36	69.2%		
	Yes	5	14.7%	29	85.3%		
Methicillin resistance						0.598	
	No	19	23.8%	61	76.3%		
	Yes	2	33.3%	4	66.7%		
Aminoglycoside resistance						0.077	*
	No	20	23.5%	65	76.5%		
	Yes	1	100.0%	0	0.0%		
Multi-drug resistance						0.139	
	No	17	22.1%	60	77.9%		
	Yes	4	44.4%	5	55.6%		

		Cured outcome			
		No	Yes		
		n (%)	n (%)		
Total		21 (24.4)	65 (75.6)		
Biofilm formation					
Positive (n=35; 40.7%)		7 (20.0)	28 (80.0)		
	Multi-drug resistance				
	Yes (n=5; 14.3%)	2 (40.0)	3 (60.0)		
	No (n=30; 85.7%)	5 (16.7)	25 (83.3)		
	Methicillin resistance				
	Yes (n=1; 2.9%)	0 (0)	1 (100)		
	No (n=34; 97.1%)	7 (20.6)	27 (79.4)		
	Haemolytic activity				
	Yes (n=10; 28.6%)	0 (0)	10 (100)		
	No (n=25; 71.4%)	7 (28.0)	18 (72.0)		
	Staphyloxanthin production				
	Yes (n=27; 77.1%)	4 (22.2)	14 (77.8)		
	No (n=8; 22.9%)	2 (25.0)	6 (75.0)		
Negative (n=51; 59.3%)		14 (27.5)	37 (72.5)		
	Multi-drug resistance				
	Yes (n=4; 7.8%)	2 (50.0)	2 (50.0)		
	No (n=47; 92.2%)	12 (25.5)	35 (74.5)		
	Methicillin resistance				
	Yes (n=5; 9.8%)	2 (40.0)	3 (60.0)		
	No (n=46; 90.2%)	12 (26.1)	34 (73.9)		
	Haemolytic activity				
	Yes (n=24; 47.1%)	21 (87.5)	3 (12.5)		
	No (n=27; 52.9%)	25 (92.6)	2 (7.4)		
	Staphyloxanthin production				
	Yes (n=26; 51.0%)	15 (57.7)	11 (42.3)		
	No (n=25; 49.0%)	12 (48.0)	13 (52.0)		